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At the commencement of this study, it was apparent that antiretroviral therapy (ART) 
improved neurodevelopmental outcomes of children infected with HIV. Little was known 
about the long-term outcomes in infants who commenced early ART, or whether there 
would be consequences of temporary ART interruption.  
We conducted a prospective, longitudinal, observational study to determine the 
neurodevelopmental outcomes of children perinatally infected with HIV on different ART 
strategies from the Children with HIV Early antiRetroviral treatment (CHER) trial. We 
compared the outcomes of children whose ART was deferred to children who started 
early ART but with planned interruption of treatment.  
We also assessed the neurodevelopmental outcomes at 11months of age in a cohort of 
children perinatally infected with HIV, who started ART within the first few weeks of life. 
The Griffiths mental development scales (GMDS) were used to assess neurodevelopment 
at 11, 20, 30, 42 and 60 months, and the Beery-Buktenica developmental tests of visual 
motor integration were performed at 60 months.  
HIV-exposed uninfected (HEU) and HIV-unexposed (HU) children from similar 
neighbourhoods were enrolled for comparison. Mixed model repeated measures were 
used to compare groups over time.  
We found that children whose ART was deferred, had worse locomotor and general 
development in the first year of life compared to those who started treatment early and 
whilst asymptomatic with planned interruption. However, by five years of age the GMDS 
scores were similar.  
Children who started very early ART at a median age of 6 days, had similar GMDS scores 
at 11 months of age to the early treatment arm on CHER, who had started ART at median 
of 8 weeks.  
During the study we noted that children developed HIV encephalopathy, despite being on 
ART, including some with viral suppression. These children were followed for a median 
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or 6.2 years and most recovered. This suggested a temporary insult, possibly due to 
inflammation associated with immune reconstitution that then resolved over time.  
An important finding was the visual perceptual deficit noted in HIV-infected children, 
compared to uninfected controls at 5 years of age. 
This study demonstrated that initiation of ART at a young age in an asymptomatic HIV-
infected cohort had encouraging neurodevelopmental outcome at 5 years, apart from 
visual perception which was noted regardless of ART treatment strategy. Planned 
treatment interruption did not affect neurodevelopmental outcome by 5 years of age, but 
this was with careful clinical surveillance.  
Longer-term outcomes in older children would continue to provide further knowledge 




Met die aanvang van hierdie studie, was dit duidelik dat antiretrovirale terapie (ART) die 
neurologiese ontwikkelings uitkomste van kinders met HIV besmetting verbeter het. 
Daar was 'n gebrek aan inligting oor die langtermyn uitkomste van kinders wat vroeë 
ART behandeling gekry het, en of daar gevolge sou wees vir tydelike onderbreking van 
ART. 
Ons het 'n voornemende, langtermyn, observasionele studie na die neurologiese 
ontwikkelings uitkomste van kinders wat perinataal met MIV besmet was, en op 
verskillende ART behandelings strategieë, gedoen om die uitslae te vergelyk met die van 
kinders met MIV en wat op vroeë antiretrovirale behandeling is. Ons het die uitkomste 
van kinders wie se ART behandeling uitgestel is vergelyk met die van kinders wat ART 
behandeling vroeg begin het en beplande onderbreking van behandeling ondergaan het, 
in die Children with HIV early antiretroviral treatment (CHER) studie.  Ons het ook die 
neurologiese ontwikkeling uitkomste op 11 maande van ouderdom in 'n groep van 
kinders wat perinataal met MIV besmet was, en wat ART binne die eerste paar weke van 
die lewe begin het, geassesseer. 
Die Griffiths Mental Development Scales (GMDS) is gebruik om die neurologiese 
ontwikkeling van kinders op 11, 20, 30, 42 en 60 maande te bepaal, en die Beery-
Buktenica ontwikkelings toetse van visuele motoriese integrasie is uitgevoer op 60 
maande. MIV-blootgestelde onbesmette (HEU) en MIV-onbesmette (HU) kinders van 
soortgelyke buurte is ingeskryf vir 'n vergelyking. 'n Gemengde model herhaal maatreëls 
is gebruik om groepe oor ‘n tydperk te vergelyk. 
Ons het gevind dat kinders wie se ART uitgestel is, slegter lokomotoriese en algemene 
ontwikkeling getoon het in die eerste jaar, in vergelyking met diegene wat behandeling 
vroeg begin het wanneer hulle asimptomaties was en wat beplande onderbreking van 




Kinders wat vroeë ART behandeling by 'n gemiddelde ouderdom van 6 dae begin, het 
soortgelyke GMDS tellings op 11 maande van ouderdom gehad as die van die vroeë 
behandeling arm op CHER, wat ART by mediaan van 8 weke begin het. 
Tydens die studie is opgemerk dat kinders MIV enkefalopatie ontwikkel, ten spyte 
daarvan dat hulle op ART behandeling was, insluitend 'n paar wat virale onderdrukking 
gehad het. Hierdie kinders is opgevolg vir 'n mediaan van 6,2 jaar en die meeste van hulle 
het herstel. Hierdie was 'n aanduiding van tydelike skade, waarskynlik weens 
inflammasie, gepaartgaande met immuun-herstel, wat daarna met verloop van tyd 
opgeklaar het 
'n Belangrike bevinding was die opmerking van 'n visuele perseptuele gebrek in kinders 
wat met MIV besmet is, in vergelyking met die onbesmette kontroles op 5 jaar van 
ouderdom.  
Hierdie studie het getoon dat die aanvang van ART behandeling op 'n jong ouderdom, in 
'n asimptomatiese MIV-besmette groep, bemoedigende neurologiese uitkomste op 5 jaar 
getoon het. Die bevinding is tenspyte van visuele persepsie wat ongeag die ART 
behandelings strategie opgemerk was. Beplande behandeling onderbreking het geen 
invloed op die neurologiese uitkomste teen die ouderdom van 5 jaar aangedui nie, 
maar hierdie met noukeurige kliniese toesig.  





I dedicate this work to the children of Africa. 
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Introduction 
Neurological manifestations during the early years of the HIV epidemic 
Human immunodeficiency virus (HIV) infection in children was first described in 1983, 
antedating effective treatment by 12 years.[1] Early clinical descriptions of HIV infection 
included neurological manifestations as part of the disease process. Epstein was the first 
to recognize the HIV’s impact on the developing brain. He described developmental 
delays, predominantly in motor milestones, perceptual motor abilities and expressive 
speech.[2]. CT scans of HIV infected children’s brains often showed cerebral atrophy with 
symmetrical calcification of the basal ganglia and/or periventricular white matter. These 
findings were mostly associated with advanced symptomatic disease.[2]  
Delay of motor milestones is a prominent feature in younger HIV infected children.[3] 
Neurodevelopmental delay can be as a direct result of the effects of HIV in the brain, or 
from indirect effects such as systemic illness, poor nutrition, maternal illnesses and 
psychosocial stressors. Secondary central nervous system (CNS) complications may also 
occur e.g. CNS infections, neoplasms or cerebrovascular accidents.[4-6] Neurological 
signs, especially if progressive, predicted mortality in HIV infected children.[2, 7]  
HIV encephalopathy 
HIV penetrates the infant’s brain very early, at time when the brain is growing rapidly 
and vulnerable to insults.[8-10] The brain is in its most rapid growth period during the 
first 20 postnatal weeks and by the age of 3 years, the average weight is almost that of an 
adult. Branching, myelination and organisation of neurons occur, along with selective 
pruning and apoptotic programming.[11]  
HIV entry into the CNS is through infected monocytes and causes neuronal injury directly, 
or indirectly through the host inflammatory response, which may affect active 
synaptogenesis and organization of neurones in the developing brain.[12] As a result, 
neurological insults occur with variable clinical manifestations and the age for developing 
HIV encephalopathy (HIVE) is variable.[2, 5, 9, 13, 14] Younger children are particularly 
vulnerable with those under 3 years of age demonstrating higher rates failure to thrive, 
development and cognitive abilities.[15] 
1
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Due to varying descriptions and definitions by early investigators, a working group of the 
American academy of Neurology AIDS task force in 1991 developed appropriate 
nomenclature and described HIV-1 associated progressive encephalopathy of childhood 
with criteria for clinical diagnosis.[16] (See appendix 1) 
Three additional HIVE patterns were also described: Static (no further loss of 
developmental milestones but following a trajectory slower than normal development), 
plateau (no new developmental skills acquired) and subacute progressive (loss of 
previously acquired developmental skills).[5, 10] 
Clinical signs for HIVE occurring in first year of life, presumed due CNS insults from in-
utero HIV infection and CNS insults were also described.[14] These include: 
• encephalopathy that developed before 1 year of age
• reduction of intrauterine brain growth
• very low levels of cerebrospinal fluid (CSF) HIV-1 RNA
• occurrence at a higher than expected CD4+ T-cell percentages and counts
• not prevented by intrauterine exposure to Zidovudine
Effects of antiretroviral therapy: 
Antiretroviral therapy demonstrated benefits for neurodevelopment and cognitive 
function in children with HIVE, first AZT and then combined ART.[17-20] However not 
all deficits were reversible, and children would revert to a static encephalopathy, those 
with an early AIDS-defining (Centers for Disease Control and Prevention (CDC) class C) 
illness.[21-24]  
Faye et al showed that early ART multidrug therapy (before the age of 6 months) had an 
improved effect on neurodevelopment compared to when ART was deferred until after 6 
months of age.[25] There were few reports on the neurodevelopmental outcome of 
children in in Africa. Van Rie et al described the neurodevelopmental benefit of children 
enrolling in care and starting ART at a younger age.[26] 
Starting ART as early as possible after the primary infection would prevent the early 
effects of the virus on the immune system and neurodevelopmental deficits. 
2
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The CHER Trial: 
Although there was evidence for improved outcomes after starting ART early, concern 
remained about the risk for resistance after exposure to drugs used for prevention of 
mother to child transmission (PMTCT) and the potential for toxicity or resistance 
associated with lifelong ART. The Children with HIV Early antiRetroviral treatment 
(CHER) trial was designed to compare early time-limited ART with deferred ART. The 
strategy was that early time limited ART initiated close to primary infection would 
prevent disease progression and safely allow a subsequent period off ART, thus 
preserving future treatment options and preventing toxicity.[27, 28] 
HIV+ infants were recruited between 6 and 12 weeks of age from community clinics in 
2005-2007, from the prevention of mother to child treatment (PMTCT) program, at two 
South African study sites: The Children’s Infectious Diseases Clinical Research Unit at 
Tygerberg Academic Hospital, Cape Town and the Perinatal HIV Research Unit in Soweto, 
Johannesburg. Those with CD4 ≥25% were randomized to one of three treatment 
strategies:  
i) ART deferred until indicated (ART-Def),
ii) Early limited ART for 40 weeks (ART-40W),
iii) Early limited ART for 96 weeks (ART-96W).
Continuous ART was initiated (in ART-Def) and reinitiated (in ART-40W and ART-96W) 
when the CD4 declined <25% in the first year of life and <20% thereafter, or for severe 
stage B or C disease according to CDC standards. After a median of 4.8 years, the 
superiority of early time-limited over deferred continuous ART was confirmed.[27, 28] 
The CHER trial started in July 2005 and formally ended on 31 August 2011. Of the 377 
infants reported in the main trial, 115 were enrolled in Cape Town. 
A nested neurodevelopmental sub-study was conducted in Cape Town. Outcomes from 
this neurodevelopmental sub-study are the main focus of this PhD, results are reported 
in chapters 2, 3 and 4. 
3
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Neurodevelopmental assessment in young South African children. 
The Griffiths Mental Development Scales (GMDS) was selected as the assessment tool of 
choice. [29] There were no comprehensive neurodevelopmental assessment tools 
standardised for South African children. The advantage of the GMDS is that it assesses 
children from 0-8 years, has been used extensively in South African children and 
translated into the local languages: Xhosa and Afrikaans. The most recent edition (GMDS-
ER) was updated involving researchers from Nelson Mandela Metropolitan University, 
South Africa and most test items were appropriate for South African Children.[30, 31] 
However, standard scores and age equivalents were developed from appropriately 
developing British children.[30, 32] 
The Beery-Buktenica developmental tests of visual-motor integration, visual perception 
and motor-coordination (6th edition) were also administered.[33] These tests are 
commonly used in South Africa in clinical and research settings. 
Since the test results have foreign normative values, HIV uninfected control groups were 
enrolled for comparison. Children perinatally unexposed to HIV and children perinatally 
exposed to HIV but uninfected from the same communities as the CHER children, were 
enrolled from an interlinked vaccine study. [34] As children enrolled on this study were 
from impoverished environments, we expected an increasing gap between acquired 
abilities over time. Therefore, neurodevelopmental trajectories of children from similar 
neighbourhoods were essential for correctly identifying neurodevelopmental delay. 
Illustrating the importance of controls, we described a decline in their scores.[35] 




Central theme of this thesis: 
Is early treatment better for early childhood neurodevelopment? 
Study hypothesis: The neurodevelopmental outcome of children starting ART early will 
be better than that of children where the treatment has been delayed and will be similar 
to a control (HIV uninfected) group. 
This work is divided into five chapters to answer this question. 
Chapter 1: 
A review of the effects of HIV on neurodevelopment 
An extensive literature review was conducted to summarise the neurodevelopmental 
outcomes of children infected with HIV including those on a variety of ART regimens and 
from a wide range of resource availability settings.  
A number of deficits were identified in children infected with HIV despite ART. This 
review highlighted the neurocognitive disease burden for future generations of school-
age children and adolescents. 
Chapter 2: 
The effect of early antiretroviral therapy on neurodevelopment 
The questions from 2005 were: Is it safe to start ART early in asymptomatic children? 
What about toxicity or developing resistance? The prevailing opinion in South Africa at 
the time, particularly amongst politicians and the media, was that ART was toxic and HIV 
diagnosis was highly stigmatised.[36, 37] These considerations led to the international 
community announcing the Durban Declaration in 2000.[38] 
In chapter 2 the early neurodevelopmental outcomes at 11 months of perinatally HIV 
infected children on the CHER trial, who started ART early were compared to those whose 
treatment was deferred. Participants were randomised into early and deferred treatment 
5
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groups according to the CHER protocol, which strengthened the study design. Of the early 
ART group 59/64 (92%) were assessed before the planned interruption phase. 
Hypothesis: Early ART would be better for neurodevelopmental outcomes in children 
with HIV. 
Chapter 3: 
The effect of planned treatment interruption on neurodevelopment  
In this prospective, longitudinal, observational study of the neurodevelopmental 
outcomes of children on the different treatment arms of the CHER trial were compared.  
The Griffiths mental development scales (GMDS) were performed at 11, 20, 30, 42 and 60 
months, six subscales and a global score, and the Beery-Buktenica developmental tests 
for visual motor integration at 60 months.  
Primary Objective: To compare the neurodevelopmental outcome of 5 groups of children 
over 5 years: 
1. ART is deferred until clinical or immunological disease progression (effect of ART on
the CNS is delayed, but effect of the virus is observed).
2. ART is started early but is given for a shorter period (until 1st birthday)
3. ART is started early and is given for a longer period (until 2nd birthday)
4. Controls who are perinatally HIV exposed and uninfected
5. Controls who are perinatally HIV unexposed and uninfected
Hypothesis: There will not be a negative effect on neurodevelopmental outcomes of 
perinatally HIV infected children interrupting ART after an early limited period on ART. 
Neurodevelopment will be similar to uninfected controls.  




Clinical trajectory of HIV encephalopathy 
The CHER trial was the first large randomized study of children perinatally infected with 
HIV who commenced early ART. We noted that the trajectory of clinical signs for HIVE 
was different to cases described in the pre-ART era. Children on early ART developed 
HIVE, although with milder deficits and subsequent recovery. This had not previously 
been described in detail. This paper was co- first authored with Dr Steve Innes. 
Chapter 5: 
Effects of starting very early antiretroviral therapy on neurodevelopment 
Hypothesis: The early neurodevelopment of infants starting ART in the first few days of 
life will be within the normal range. 
Contemporary thinking was that immediate ART could prevent or decrease the size of 
the HIV reservoir in brain.[39] However there were concerns of toxicity to the rapidly 
developing neonatal brain, especially if ART over-dosing occurred due to difficulty 
measuring syrups. [40] In chapter 5, the neurodevelopmental outcome at 11.5 months of 




Review of literature on the neurodevelopmental outcomes of children 
perinatally infected with HIV 
Unlike many other chronic illnesses, there is no classical phenotype of 
neurodevelopmental deficits in children perinatally infected with HIV. 
Neurodevelopmental outcome studies are not uniform, and outcomes are varied. This 
may be due to multiple factors, including timing of infection (in utero, intra-partum or 
post-natal) and starting treatment, different ART regimens, viral properties, host 
conditions, assessment tools and other environmental factors. 
A comprehensive literature survey was conducted to summarise evidence on 
neurocognitive deficits due to HIV infection and was published in a supplement on 
adolescent HIV in the Journal of the International AIDS Society. The outcomes of school-
aged children were described as there was very little published data on adolescent 
outcomes at that time (2013).  




We noted that neurocognitive deficits may be subtle and not as obvious as HIV 
encephalopathy described in the pre-ART era; CNS insults from HIV were variable as 
there were multiple causal factors; those with AIDS defining illnesses had worse 
outcomes; and children perinatally infected with HIV were at higher risk for psychiatric 
and mental health problems.  
This review described the substantial and underappreciated burden of HIV on the 
neurodevelopmental outcomes of children and encouraged all physicians to be on the 
alert for neurodevelopmental deficits. 
This publication has been cited 137 times (PubMed September 2019), probably because 
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Abstract
Globally, an estimated 3.4 million children are living with HIV, yet little is known about the effects of HIV and antiretroviral
treatment (ART) on the developing brain, and the neurodevelopmental and behavioural outcomes of perinatally HIV-infected
(PHIV) adolescents.
We reviewed the literature on neurodevelopmental outcomes in PHIV children and adolescents, and summarized the current
evidence on behaviour, general cognition, specific domains, hearing and language, school performance and physical disabilities
due to neurological problems.
Evidence suggests that PHIV children do not perform as well as controls on general cognitive tests, processing speed and
visualspatial tasks, and are at much higher risk for psychiatric and mental health problems. Children with AIDS-defining
diagnoses are particularly at risk for poorer outcomes.
A striking finding is the lack of published data specific to the adolescent age group (1025 years), particularly from resource-
constrained countries, which have the highest HIV prevalence. In addition, extreme heterogeneity in terms of timing and source
of infection, and antiretroviral experience limits our ability to summarize findings of studies and generalize results to other
settings.
Due to the complex nature of the developing adolescent brain, environmental influences and variation in access to ART, there
is an urgent need for research on the longitudinal trajectory of neurodevelopment among children and adolescents perinatally
infected with HIV, especially in high burden resource-constrained settings.
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Introduction
An estimated 3.4 million children are living with HIV world-
wide [1], 28% of whom have started antiretroviral therapy
(ART) [2]. Yet, little is known about the effects of HIV and ART
on the developing brain and the neurodevelopmental out-
comes of perinatally HIV-infected (PHIV) adolescents.
In neuropsychological terms, adolescence spans the age
range of 1025 years [3], which in 2013 includes those
born between 1988 and 2003. Over this time period, the
management of PHIV infants, children and adolescents
changed dramatically. Before the introduction of ART in 1995,
50% of PHIV children died before the age of two [4], with a
few slow progressors surviving to adolescence [5]. Prior to
1997, children in Europe and the United States may have
received multiple antiretroviral regimens, including those
that would now be considered suboptimal therapy. In 1997,
combination ART was introduced in the United States. Since
2004, access to ART has expanded rapidly in resource-poor
settings and depending on the country, 2880% of treat-
ment-eligible children have initiated ART [2].
Context-specific differences in access to ART over the past
two decades have resulted in great variability in disease
severity and in exposure to ART among PHIV adolescents:
some started ART soon after HIV infection, prior to clinical
diagnosis of neurodevelopmental delay [6]; some initiated
ART after the diagnosis of HIV encephalopathy [7,8], resulting
in neurological deficits that remained permanent despite
ART [9,10]; other PHIV adolescents are slow progressors
and remain ART-naı̈ve as they have not yet reached the ART
eligibility threshold [2]. The source and time of infection
cannot always be determined in HIV adolescents, espe-
cially in settings with generalized HIV epidemics.
There is also substantial heterogeneity in the literature
in terms of the age of study participants. Most published
studies have focused on younger children aged 612 years
[1113] or 716 years [14], crossing from childhood to ado-
lescence. The issue is further compounded by the measures
used to assess functionally relevant outcomes for PHIV
adolescents in diverse cultural settings. In some settings,
the emphasis may be on achieving good school grades to





maximize employment options, while in other settings
adolescents may be more concerned about starting a family
and providing resources to support a household or extended
family.
Given this extreme heterogeneity in the age of study
participants, severity of disease, antiretroviral experience,
and the definition and measurement of outcomes, we
reviewed the literature on neurodevelopmental outcomes
in PHIV adolescents.
We conducted a literature search using the following key
words: neurodevelopment/al, development, neurocognitive,
cognitive, adolescents, youth, perinatal/vertical HIV-infected,
HIV exposed, school performance, adaptive functioning,
hearing and neuroimaging. We reviewed bibliographies and
relevant articles from different contexts globally, limited
to the most recent papers. We included all ages spanning
adolescence. The original aim was to review evidence on
neurodevelopmental outcomes among perinatally HIV-
infected adolescents. However, the paucity of strictly adoles-
cent data was striking. In the absence of these data, we drew
on published studies of neurodevelopmental in younger
children with HIV as a guide to what could be expected to
impair neurodevelopment in adolescence.
Neurodevelopmental changes during
adolescence
The key developmental tasks during adolescence are to
develop an identity, to become more independent, and to
consider the future in terms of career, relationships, families,
housing, etc. [15]. Traditionally, adolescence is viewed as the
age when abstract thought develops, together with improve-
ments in memory, language, processing speed, attention
and concentration [16]. A more contemporary view is that
the major dimensions of cognitive development during
adolescence are the refinement of executive control and
the attainment of a more conscious, self-directed and self-
regulating mind [1719]. Central to these are executive
function (EF) processes such as voluntary response inhibi-
tion, working memory, response planning, improved proces-
sing speed, cognitive flexibility, and rule-guided behaviour
[18,19].
While the adolescent’s brain does not increase substan-
tially in volume, changes in maturation reflect reorganization
of regulatory systems and correlate with neurocognitive and
behavioural outcomes [17]. During adolescence, white mat-
ter increases in a linear fashion with increased myelination
and re-organization with synaptogenesis and pruning, espe-
cially in the frontal lobes and prefrontal cortex, which serve
as the governor of cognition and action [17,18]. Maturational
changes are influenced by numerous factors including
genetic and environmental factors as well as overall health
status, resulting in variation between children and within the
same child for the various domains of neurodevelopment.
The impulsive and risk-taking behaviour of adolescents is also
thought to be a consequence of the interaction of social
context and the development of judgment, decision-making
and internal control [17,20].
Neuropathology caused by HIV is most evident in basal
ganglia and cerebral white matter. Neuronal loss is prominent
in the prefrontal cortical regions, which may cause difficulty
in complex mental processing [21]. These are the regions
where myelination and remodelling of synaptic connections
are still occurring during adolescence [22,23]. When coupled
with the high risk for psychiatric difficulties in PHIV
adolescents, the relationship between impaired EF and risk-
taking behaviour can be compounded.
General cognition
The most common measure of neurodevelopmental outcome
is general cognition. General cognitive assessments provide a
global score of performances in various domains. In this case,
appropriate perinatally HIV-unexposed (PHU) children can be
used as controls [12]. Neighbourhood-matched perinatally
HIV-exposed uninfected (PHEU) children can be used to
control for confounding effects of prenatal HIV exposure, ART
exposure and maternal illness, etc. [11,24], but they should
not be seen as an ideal control group.
Table 1 summarizes recent studies of general cognition in
PHIV children. Most neurocognitive assessment studies of
PHIV children have been performed in the United States
and Europe [14,2527], though some studies from other
continents have been published [1113,24]. There are many
differences between the study populations, with each group
having particular areas of vulnerability of the brain and life
experiences (e.g., higher drug abuse and lower adherence in
some parts of the United States; higher poverty and lower
access to comprehensive treatment in some limited-resource
countries; different treatment when infants). Overall, PHIV
children and adolescents perform more poorly in neurode-
velopmental assessments than PHU controls or national
norms [11,13,24], although in some studies there were no
significant differences between groups [12,26,27]. For chil-
dren in the United States, better cognitive outcomes have
been associated with having a biological parent as caregiver,
higher family income level, and higher caregiver cognitive
function [14]. In PHIV children with less severe disease
progression (WHO clinical stage I or II) and those on ART
without a history of an AIDS defining illness, overall cognitive
development has been found to be similar to that of PHEU
children [14] although still significantly poorer than PHU
children [13].
Martin and colleagues evaluated predictors of cognitive
decline in older children in the United States who had been on
ART for at least a year. Overall, PHIV children on ART remain
at risk for developing CNS disease, with children with minimal
to moderate CT brain scan abnormalities scoring significantly
lower than children with normal scans on composite mea-
sures of cognitive ability [21]. The risk in asymptomatic
adolescents was confirmed in a small pilot study which found
a higher rate of neurocognitive impairment in asymptomatic
adolescents compared to adults 60 years old (67 vs. 19%)
[28].
Few studies have addressed the effect of ART initiation on
cognitive development in PHIV school-age children and
adolescents in low- and middle-income countries. In a cohort
of Thai children, cognitive function did not improve in
response to ART, even in children who achieved virological
suppression and immunological recovery [11]. There were





Table 1. Summary of recent studies on general cognition in HIV-infected children




22 PHIV Median 9.46 years
(613.5)
SON-R No gross cognitive deficits
compared to normative values
Median age HAART initiation 5.6 years






716 years WISC-IV Scores significantly lower for PHIV/C group after
adjusting for covariates 77.8 vs. 83.4 and 83.3










Mean FISQ 91.7 vs. 100.5 12 were on ART





















WISC-IV or WASI Median FISQ of PHIV/noC fell within normal range;
Median FISQ of HIV/C in below average range
Median age: ART initiation: 3.1 years;









WISC-III Mean FISQ of HIV and affected groups significantly
lower than healthy controls
79 vs. 88 vs. 96 pB0.01





284 PHIV, 155 PHEU,
164 PHU
Median age 9 years
(112)
WISC-Thai No difference between early and deferred ART
initiation RCT arms. PHIV children performance
worse than PHEU and PHU on IQ
Early versus deferred HAART at enrolment from
1 to 12 years of age
Hoare et al. 2012
South Africa [24]
12 PHIV









PHIV/C Perinatally HIV-infected with a previous class C event.
PHIV/noC Perinatally HIV-infected with no past history of class C event.
KABC Kaufman Assessment Battery for children.
KABC-2 Kaufman Assessment Battery for children, 2nd edition.
SON-R Snijders-Oomen nonverbal intelligence test for children and adolescents (abridged).
WASI Wechsler Abbreviated Scale of Intelligence.
WISC-R Wechsler Intelligence Scale for Children Revised.



































































































also similar neurodevelopmental and neuropsychological
outcomes in Thai and Cambodian children between early
and deferred ART groups, although both groups performed
worse than PHEU children [29]. A small study of younger
South African children (median age five years) also failed to
observe neurodevelopmental improvement following ART
initiation [9].
Specific domains of cognitive development
Global cognitive scores may overlook subtle deficits in one or
more areas specific to PHIV children and may affect their
performance on a different level [26,30,31]. For example, even
in PHIV children with global cognitive scores in the normal
range, EF may be impaired, especially in children with cortical
atrophy, lower fractional anisotropy of the corpus callosum
and those with CD4 counts below 500 cells/mm3 [21,24].
Specific domains may be measured as subtests on cog-
nitive assessments or by a test specifically designed for that
purpose. The development of EF starts in childhood, but is
highly important in the development of adolescents. EF is a
composite of different domains including processing speed,
response inhibition, working memory, response planning,
cognitive flexibility with task switching, attention and con-
centration [32]. Processing speed is associated with increased
capacity for working memory, enhanced inductive reasoning
and greater accuracy in solving arithmetic word problems, and
consistently predicts performance on cognitive tasks [16].
Table 2 summarizes studies that explore the impact of
HIV on important neurocognitive domains. PHIV children
have been found to perform significantly poorer in EF
tasks, particularly in terms of processing speed [13,14,26,33],
memory [12,14,21,24,34] and attention [13]. Lower scores on
visualspatial processing have also been described in younger
PHIV children [27,35].Visualspatial processing is important
for adolescents as it impacts on reading, writing and learn-
ing. PHIV children have been shown to be slower and less
accurate on pattern recognition [26], and to have lower
scores than controls on sequential processing, simultaneous
processing [36], planning/reasoning [13] and visual memory
[24].
Adaptive functioning
Adaptive functioning has been defined as the ability to
function effectively in a number of settings requiring social
and problem solving skills, including school, home and social
settings [37]. Cognitive assessments may not be the appro-
priate measurement tools to capture the ability of children
and adolescents to function in real life situations. For
example, in child-headed households in resource-constrained
settings, children are required to take far more responsibility
than in resource-rich countries. Measuring adaptive function-
ing, as previously used in younger children, may provide a
more meaningful way of assessing how adolescents are
functioning in their own environments. There is conflicting
evidence on the correlation of scores. Gosling et al. found
significant weakness in adaptive functioning compared with
cognitive functioning in PHIV children [38]. In contrast,
Smith et al. found some disparity, with higher scores in
adaptive function at lower cognitive scores [14]. As the
number of PHIV children grow, further research on this is
needed to determine whether measuring adaptive function-
ing is a useful measurement tool for neurodevelopmental
outcomes in PHIV adolescents in less developed settings.
The interplay between HIV, neurodevelopment,
behaviour and mental health
Several studies have focused on the burden of psychiatric
problems and mental health functioning impairment
in PHIV children and the interplay with EF, risk-taking
behaviour and treatment adherence.
A study in the United States observed a 25% prevalence of
mental health problems among PHIV children and adoles-
cents, well above that of the general population though
lower than the 38% rate observed in the PHEU comparison
group [39]. Caregiver characteristics (psychiatric disorder,
limit-setting problems and health-related functional limita-
tions) and child characteristics (younger age and lower IQ)
were most predictive of the occurrence of mental health
problems. Another US study documented that 18% of 617
year old PHIV children had a lifetime history of psychiatric
medications, 13% were on medication (largely stimulants
and antidepressants) for psychiatric problems and 22% had a
past or current history of non-medication psychological
intervention [40].
There is a strong association between psychological and neu-
rocognitive functioning. In a study in Atlanta and New York
City, depressive symptoms in PHIV adolescents were best
predicted by a combination of negative coping skills and poor
neuropsychological functioning. Conduct disorder problems
were directly associated with neuropsychological functioning
(cognitive inflexibility) and negative coping skills [41]. A study
in New Zealand reported that risky personality and perfor-
mance on the neuropsychological and EF tests were signifi-
cant predictors of risk-taking [42]. Furthermore, psychiatric
disorders and behavioural health challenges in PHIV
children can lead to poor ART adherence, risk-taking behav-
iour, including risky sexual behaviour, precocious sexual
debut, teenage pregnancy and substance abuse [40,4348].
These findings add weight to the increasing concern
about long-term neurodevelopmental problems among
PHIV adolescents [8,49] and the burden that these pose
for individuals, families and the education and health care
systems.
Language and hearing
As children transition to early and middle adolescence,
language and reading skills are the critical building blocks
for literacy and future academic success, with an important
transition from ‘‘learning to read and reading to learn’’ [50].
There is evidence that verbal skills are negatively affected in
PHIV children [14,24,36,50,51]. In a large study in New York
City, vocabulary and reading were worse in PHIV youths
compared to PHEU, even after adjusting for demographic
variables [50]. In contrast, Rice et al. in a multisite US
(including Puerto Rico) study found that both PHIV and
PHEU performed poorly on verbal tests, but there was no
difference between the two groups [51].





Table 2. Specific neurocognitive domains affected in perinatally HIV-infected children
Study Participants Age (range) Measure Findings
Processing speed:
Koekkoek et al. 2008 [26]
The Netherlands




Significantly slower compared to age-appropriate norms







Lower scores on processing speed for PHIV/C compared to PHIV
/NoC and PHEU. PHIV/NoC and PHEU scores were similar




617 years WISC-IV coding recall Higher peak viral load (100 000 copies/ml)and lower nadir
CD4% (B15%) associated with slower speed










Test of variables of attention Worse visual, auditory and overall reaction time than HIV-community
age matched
Set Shifting:







Significantly slower compared to age-appropriate norms
Better outcomes with longer HAART duration
Verbal Fluency: (EF in the verbal domain)





Verbal fluency Significantly lower scores compared to age appropriate norms






Semantic fluency Significantly lower than HIV-negative controls from same
neighbourhood
Memory





6.314.9 yrs WISC-digit span and information
Story recall
Rey Complex figure






612 years KABC Sequential processing
(Immediate memory recall)
HIV significantly lower scores than HEU
No difference between PHIV and HIV- groups
Martin et al. 2006 [21]
USA
41 PHIV Mean 11.2 yrs
(616)
WISC III  working memory:
Digit span backwards
Arithmetic
Significantly lower scores in those with abnormal CT brain scans



































































































Table 2 (Continued )
Study Participants Age (range) Measure Findings







WISC IV digit span Backward
Visual memory:
Rey complex figure
Groups performed similar for working memory
Visual memory significantly worse in PHIV compared to HIV-
controls





716 years WISC IV:
Working memory
2 to 5 fold increased risk of impairment for HIV/C group compared
to PHEU group
Visual spatial memory/integration





Amsterdam neuro-psychological task: visuospatial
memory
Significantly lower scores in visuospatial working memory compared
to age-appropriate norms.







Beery Visual Motor Integration No difference between early and deferred ART initiation RCT arms
PHIV children performance worse than PHEU and PHU








Rey complex figure test
Significantly worse than HIV-negative controls
PHIV/C: Perinatally HIV-infected with a previous class C event.



































































































While CD4 cell count, HIV viral load and CDC Classification
were not associated with verbal scores in the New York City
study [50], two other US studies found that a history of
an AIDS-defining illness was associated with verbal compre-
hension impairment [14,51]. In addition, Rice et al. found
that after controlling for cognitive and hearing impairment,
children who were PHIV with detectable viral load and ART
initiation less than six months of age had an increased risk of
language impairment. Other risk factors for language impair-
ment combined with cognitive or hearing impairment were
race/ethnicity, caregiver’s education and intelligence quoti-
ent (IQ) status and having a non-biological parent as
caregiver [51].
Adjustment for hearing deficits in language assessment of
PHIV children is important as the prevalence of hearing
loss in PHIV children is high and ranges from 20% in higher
income countries to 38% in low-resource settings [52,53].
In resource-poor settings, hearing loss was largely conduc-
tive, including chronic suppurative otitis media and dry
tympanic membrane perforations, which may reflect the
lack of consistent otological care, whereas in well-resourced
settings more children had sensorineural hearing loss [54],
which may possibly be related to measurement in the United
States. A low CD4 count and a history of AIDS-defining illness
were associated with both hearing and language impairment
[53,54].
School performance
School performance is a functional outcome that is highly
relevant in terms of future quality of life and employment
prospects [55]. Academic failure predicts problems in school-
ing and leads to an increase in school dropouts [56]. Insight
into the school performance of PHIV children is important
in order to plan appropriate resources to support this
vulnerable population. However, accurate measurement is
problematic due to the abundance of potential confounders.
A child’s school performance is dependent on numerous vari-
ables including social and family factors [55,56]. In addition,
the indirect effects of HIV infection including hearing loss,
school absenteeism due to ill health or ART management,
depression and/or social problems need to be considered
when interpreting school performance [33].
Several studies have explored school performance among
PHIV children and adolescents, and identified poorer
outcomes compared with children without HIV, with the
exception of a French study, which reported an academic
failure rate of 16%, similar to the general population [57].
Outcome measurements were highly variable and included
42% with a learning disability [25], 2733% receiving special
education [50,57,58], 15% having repeated two or more
grades [57] and 51% having failed at least one grade [59].
Limited caregiver education or intelligence level increased
the risk of poor educational outcomes [14]. There is a striking
lack of studies on academic achievement in resource-limited
countries. Although such research would be difficult to
undertake, it would provide valuable information to guide
interventions.
Physical disabilities due to neurological
problems
Physical problems due to HIV encephalopathy have been well
described in the pre-ART era [10]. There is however a paucity
of data on neurological outcomes of ART-naı̈ve PHIV child
non-progressors as well as those on ART, particularly in older
children. In Uganda, Bagenda et al. describe children with
hypotonia, hyperreflexia and delayed milestones, which
disappeared as they grew older [12]. Boivin et al. also found
motor impairment in PHIV asymptomatic children in the
first two years of life and later in childhood (ages 812 years)
[36].
Two South African studies described motor deficits
and neurological manifestations in PHIV children [9,60].
Govender et al. reported 59% abnormal neurological exam-
inations in children aged one month to 12 years, 41% with
global pyramidal long tract signs and 16% with cortical visual
impairment. However, there were many participants with
neurological sequelae due to secondary infections and the
direct effects of HIV infection are not clear [60]. Smith et al.
found evidence of motor dysfunction in 33% of ART-naı̈ve
children with no improvement after six months of treatment
[9]. In a cohort of 210 PHIV French children followed
since birth, at a median age of 15 years, three children had
persistent motor dysfunction and five had mild to moderate
physical impairment, indicating a low incidence of physical
disabilities due to neurological problems in children who
gain timely access to ART [57]. Some of the neurological
manifestations in the young child may not be reversible and
may still be evident in the adolescent. We have included
these studies to emphasize that a neurological examination
should be included when measuring functional outcomes in
PHIV adolescents.
CNS disease and stroke have been documented as causes of
death in PHIV children, adolescents and young adults in the
USA [8]. In the pre-ART era, the annual risk of cerebrovascular
events was 1.3% [61], but there are no data on the incidence
of stroke in PHIV children on ART. Similarly, the incidence
and effect of central nervous system insults caused by
infections such as tuberculosis and meningitis have not
been well documented.
Markers of HIV disease progression and
severity
Traditional markers of HIV disease progression and severity
including high plasma viral load, lower CD4 cell counts
and/or CD4%, and history of an AIDS defining illness have
been associated with poorer neurocognitive performance
[13,14,21]. In addition, some markers of vascular dysfunction
and T-cell activation have been found to correlate with global
cognitive outcomes in PHIV youth. Specifically, higher
soluble P-selectin, a marker and mediator for inflammatory
vascular disease, and lower fibrinogen (a pro-coagulant state
marker) have been associated with poorer cognitive func-
tion [62]. CD4activation and, under certain circumstances,
CD8 activation have been shown to have favourable
neurodevelopmental implications in PHIV-infected children
[63]. In a study of ART-naive Ugandan children, HIV subtype-
A was associated with higher viral loads and poorer





performance compared to subtype-D, suggesting that subtype-
A may be more neuropathogenic in children [64].
Intervention strategies
Studies have found that ART alone is not sufficient to reverse
the neurodevelopmental consequences of HIV infection
[31,65]. Highly active ART (HAART) may even contribute to
neuromotor decline over time [31,66]. The inability of ART
alone to restore HIV children to ‘‘normal’’ neuropsycholo-
gical performance is a compelling rationale to evaluate
alternative interventions for neurocognitive disability in
paediatric HIV. Despite knowledge of deficits in PHIV
children, there have been very few intervention studies. One
intervention is computerized cognitive rehabilitation training
[67,68]. Preliminary results in Uganda indicate that using
computer games for cognitive rehabilitation can be of great
benefit to PHIV children and adolescents [69]. For younger
children with HIV, caregiver training on practical strategies to
enrich the developmental milieu of these children can also
have significant neurocognitive benefit [70].
There is evidence to suggest a strong link between
psychological well-being and the immunological impact of
disease progression [71]. HIV-infected children who exhibited
signs of resilience tended to have better neurodevelopmental
functioning, socialemotional and gross motor functioning
[72]. Some approaches to fostering resilience in PHIV
children have centred around family dynamics within a
cultural framework [7376]. In a qualitative study of resi-
lience among Rwandan HIV-affected children and families
[74], Betancourt and colleagues identified five factors that
increased resilience in children and families affected by HIV:
perseverance, self-esteem/self-confidence, family unity/trust,
good parenting, and collective/communal support. Interven-
tions and strategies to leverage these resources may help to
prevent mental health problems in these children as they
grow into adolescence and adulthood [73]. Psychosocial
intervention may also significantly enhance subsequent
neurocognitive development of the child in response to the
direct physiological, psychological, social and immunological
impacts of this disease. For example, Coscia et al. showed that
home environment had a stronger association with child IQ
during the advanced than the early stages of disease [77].
Parental support has been shown to provide a stress-buffering
effect for the effects of depression in these school children,
that seemed to improve psychosocial and cognitive develop-
ment [78,79].
Discussion
Each child has their own set of unique factors that shapes
their development, making it difficult to identify the relative
contribution of different factors impacting on the neurode-
velopmental outcomes of PHIV adolescents. While HIV has
a direct effect on neurocognitive development, the effects
of deprivation and poverty, quality of home environment,
genetics, opportunistic infections, and access to care may
overshadow the effects of HIV, particularly in resource-
constrained settings.
Important variables that have been shown to affect
neurodevelopmental outcomes include caregiver mental
health or substance problems [14], orphan status and chronic
illness [60], nutritional status [60,80] formal education and
home environment [80] as well as having a biological parent
as caregiver, higher family income level and higher caregiver
cognitive functioning [14]. Given the psychosocial impact
of diagnosis and treatment, as well as the contribution of
coping with cognitive weaknesses, additional attention to
behavioural and mood symptoms associated with childhood
HIV is essential.
It is possible that ART initiation in school-aged children and
adolescents may be too late to reverse impairment. Cohorts
initiating ART earlier report better outcomes, suggesting that
earlier ART initiation is beneficial [6,29]. However, there is
inadequate evidence of the effects of long-term ART on the
developing brain. Lower nadir CD4 counts, higher viral loads
and the history of an AIDS-defining illness are associated
with poorer neurodevelopmental outcomes, further support-
ing the need for early ART initiation in children. Children
presenting with these risk factors should be offered neuro-
developmental screening as part of routine HIV care and
referral to supportive services or formal assessments where
appropriate. PHIV adolescents should be provided with
multidisciplinary support services including adherence sup-
port, reproductive health counselling and mental health and
educational/vocational planning [81]. Preliminary evaluations
of these multi-faceted interventions for PHIV adolescents
have shown good results in improving adherence and reduc-
ing risk-taking behaviours [8184].
While most studies describe the proportions of male and
female study participants, generally the data were not
analysed and compared for sex differences in outcomes.
This is possibly because it is generally accepted that the
neurodevelopment of boys and girls are similar. However,
possible sex differences in adolescent neurodevelopmental
outcomes require further exploration.
Conclusions
PHIV adolescents constitute a large heterogeneous popu-
lation. Overall, HIV children and adolescents have poorer
neurodevelopmental outcomes than uninfected peers, parti-
cularly those with more advanced HIV disease. There is also
emerging evidence that PHIV adolescents are especially at
risk for poorer psychiatric outcomes and EFs. However, the
impact of HIV on the developing adolescent brain is highly
complex, influenced by many factors and not well under-
stood. Compounding and contributory factors may include an
increased risk of substance use, risky sexual and other risk-
taking behaviours, and poorer ART adherence.
A striking finding is the paucity of data specific to the
adolescent age group (1025 years) and the lack of long-
itudinal cohort studies designed to assess the effect of HIV on
neurocognitive functioning in PHIV adolescents. While
much of the current evidence is from younger ages, evidence
from these studies provides valuable information as neuro-
developmental problems occurring at younger ages are likely
to persist in adolescence and adulthood. Furthermore, the
majority of studies on neurodevelopmental outcomes in
adolescents are from the United States and Europe, with few
studies from low- and middle-income countries which have





the highest prevalence of PHIV adolescents. Few studies
explore possible gender differences in adolescent neurode-
velopment. Finally, little is known about the complex nature
of recovery of the brain after initiation of ART. Thus, there
is an urgent need for longitudinal research assessing the
long-term effect of ART and timing of ART initiation on
neurodevelopmental outcomes of perinatally HIV-infected
adolescents by gender, particularly in resource-constrained
settings.
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Neurodevelopment of infants on early compared to deferred 
antiretroviral therapy 
When this study was designed, the recommendations for starting ART in children 
infected with HIV was to wait until they were symptomatic.[41] 
A small study by Faye et al described benefits of early antiretroviral therapy before 6 
months of age in France [25], but there were no studies from high burden settings such 
as South Africa. There were questions as to whether early ART would be safe – possible 
toxicity, or whether resistance would develop due to difficulty administering ART in 
young babies or waning adherence over time. 
We assessed the neurodevelopment of infants perinatally infected with HIV enrolled on 
the Children with HIV Early antiRetroviral treatment (CHER) trial [27, 28] using the 
Griffiths Mental Development Scales [32] at 10 – 12 months of age. Children starting early 
ART at a mean of 8.4 weeks of age were compared to those on the delayed treatment arm 
who started ART at a mean of 31.4 weeks. ART was Zidovudine, Lamivudine and 
Lopinavir/ritonavir. Uninfected controls from similar neighbourhoods were used as a 
reference group.  
We found that infants initiated on early ART had significantly better locomotor and 
general GMDS scores than those on deferred ART and were similar to uninfected controls.  
This study was one of the earliest providing evidence of the neurodevelopmental benefits 
of early ART in asymptomatic infants and provided support for the earliest possible 
diagnosis of HIV and initiation of ART in infants. 
This paper has 136 citations (PubMed Sept 2019), including in Nature.[42] 
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ISSNObjectives: To evaluate the effect of early versus deferred antiretroviral therapy (ART)
on the neurodevelopment of infants from Cape Town participating in the Children with
HIV Early Antiretroviral Therapy (CHER) trial.
Design: HIV-infected infants were randomized to early (<3 months) or deferred ART.
HIV-uninfected infants (HIV-exposed and HIV-unexposed) provide background data.
Methods: Neurological examination and Griffiths Mental Development Scales (GMDS)
were administered between 10–16 months of age by testers blind to HIV status and
randomized allocation. Mean quotients were compared using paired Student’s t-tests.
Results: Sixty-four infants on early ART and 26 on deferred ART (of potential 77 and 38
respectively on CHER trial) were assessed at median age 11 months (range 10–16). On the
GMDS, all scores were lower in the deferred arm and the General Griffiths and Locomotor
Scores were significantly lower: mean (SD)¼100.1 (13.8) vs. 106.3 (10.6) P¼0.02; and
88.9 (16.3) vs. 97.7 (12.5), P<0.01, respectively. Children with HIV who received early
ART performed as well as children without HIV except on the Locomotor subscale. Both
infected and uninfected mean GMDS scores were within the average range.
Conclusion: Infants initiated on early ART have significantly better Locomotor and
general scores on the GMDS at median age 11 months compared to infants on deferred
ART, despite careful monitoring and ready access to ART in the latter.
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Stellenbosch University https://scholar.sun.ac.zaIntroduction prior to neurodevelopmental assessments were calculatedThe prevalence of neurodevelopmental delay and/or HIV
encephalopathy in HIV-infected children from predo-
minantly well resourced countries has been reported to be
between 13 and 23% [1]. Studies from resource-limited
settings, wherein antiretroviral therapy (ART) is generally
started later, have also reported neurodevelopmental delay
[2–5]. However, few studies have prospectively evaluated
the impact of early ART on the neurodevelopmental
outcomes of HIV-infected infants, and there have been
no randomized trials evaluating this outcome. Previous
studies have frequently included infants exposed perina-
tally to other risk factors for poor neurodevelopmental
outcome such as illicit drugs [6–8].
To determine the effect of early vs. deferred ARTon early
neurodevelopmental outcomes, we compared the neu-
rodevelopmental profile on the Griffiths Mental Devel-
opment Scales (GMDS) [9] of HIV-infected infants who
started ART before 12 weeks of age with those for whom
ART was deferred until they met immunological or
clinical criteria. This was a substudy of the Children with
HIV Early Antiretroviral Therapy (CHER) trial as
previously described among children enrolled from the
Cape Town clinical site [10].Methods
This cross-sectional substudy compared neurodevelop-
mental outcomes among participants in CHER random-
ized to early versus deferred ART, and among HIV-
uninfected infants (HIV-exposed and HIV-unexposed)
participating in a linked vaccine study [11]. Children
were eligible for inclusion if they had no dysmorphic
syndromes or underlying non-HIV-related central
nervous system abnormalities. The uninfected children
were recruited from a concurrent study of pneumococcal
conjugate vaccine to provide additional data on the
GMDS for South African infants from low socio-
economic backgrounds.
In CHER, HIV-infected infants were randomly assigned
to three arms: ART deferred until clinical or immuno-
logical progression; early ART commenced before 3
months and limited to 40 or 90 weeks. In this substudy,
data from the two early ART arms have been combined.
First-line ART included three drugs: zidovudine,
lamivudine and lopinavir/ritonavir. Second-line ART
was didanosine, abacavir and nevirapine.
Baseline viral load, CD4 cell count, time on ART and
hospitalization were obtained from the study database.
Birth history and maternal education were obtained from
the charts and caregiver interviews. Hospital admissionspyright © Lippincott Williams & Wilkins. Unautho
23as days in hospital including the days of admission and
discharge. Head growth was plotted on Centers for
Disease Control and Prevention (CDC) charts.
A neurological examination and the GMDS were
performed at the study visit closest to 10–12 months
of age by one of four pediatricians blinded to HIV status
and randomized allocation. The GMDS 0–2 years was
revised and re-standardized on 665 British children in
1996 [9]. The mean (SD) quotients for general quotient
and subscales were 100.5 (11.8) and 100 (16), respectively.
Significant impairment is regarded as more than 2 SDs
below the mean. Quotients on the subscales and the
general quotient were obtained from raw scores using data
from normal British children. There are five subscales:
Locomotor measures the earliest motor milestones;
Personal-social assesses early adaptive behaviour using
interaction with the environment and skill in dressing and
feeding; Hearing and language measures early expressive
language and the ability to follow commands and identify
objects; Eye and hand coordination measures fine motor
and visual abilities; Performance measures fine motor
manipulative skill and visual spatial orientation. Standar-
dized instructions, questions and comments were
prepared in English, Afrikaans and Xhosa in accordance
with the GMDS manual. A single translator assisted all
Xhosa-speaking children.
Statistical analysis was performed with Statistica 10
(Statsoft, Tulsa, Oklahoma, USA). Comparisons between
groups were performed using either the paired Student’s
t-test or the Mann–Whitney U test for continuous
variables and the x2 and Fishers test for discrete variables
or using one-way analysis of variance using the Kruskal–
Wallis test. Mean days in hospital was compared using a
generalized linear model using the Poisson distribution
and log link function. A 95% confidence interval was
calculated where applicable and significance was estab-
lished at P value less than 0.05.
The substudy protocol was approved by the Human
Research Ethics Committee, Faculty of Health Sciences,
Stellenbosch University, registration number N05/05/
092. Written consent was obtained from the child’s parent
or guardian.Results
A total of 115 HIV-infected infants from Cape Town
participated in the parent study, 77 (67%) of whom were
randomized to the two early ART arms and 38 to the
deferred ART arm. Of these, eight infants died before
assessment (all on the deferred arm); 10 (eight on early
ART, two on deferred ART) were not enrolled as theyrized reproduction of this article is prohibited.
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Stellenbosch University https://scholar.sun.ac.zawithdrew from the parent study before scheduled
neurodevelopmental assessments. Two infants on early
ART with underlying neurological disorders (glutaric-
aciduria, fetal alcohol syndrome) were excluded.
Five infants (three on early ART and two on deferred)
were also excluded because they were assessed after the
cutoff age (two) or had unreliable scores (two) or
repeatedly missed appointment dates (one). Our analysis
included 64 infants on early ART and 26 on deferred
treatment.
Demographic information is shown in Table 1. HIV-
infected infants were predominantly girls and Xhosa-
speaking and maternal education was comparable.
Birth outcomes were comparable for weight, gestation
and mode of birth. Demographics were comparable
in the early treatment group and the unexposed
uninfected infants, except for language and gestation.
There were more Xhosa-speaking infants in the early
treatment group (86 vs. 29%) and more infants with
gestation more than 37 weeks in the HIV-infected
groups. At enrollment into CHER, the treatment groups
were comparable on mean absolute CD4 cell count
(1746 vs. 2024 cells/ml, P¼ 0.5), CD4% (34.8 vs. 34.9%,
P¼ 1.0) and plasma viral load (log10 RNA copies/ml:
5.66 vs. 5.64, P¼ 0.8).
Mean age of starting ARTwas 31.4 weeks in deferred and
8.4 weeks in early ART (P< 0.01). Twenty-four (92%)
infants in deferred ART group were on ART at
assessments. Mean time on ART before assessments
was 18.7 weeks in deferred and 40.9 weeks in early ART
(P< 0.01). According to the CHER protocol, treatment
interruption was planned after 40 weeks of early ART for
some participants [10]. Five infants on early ART, whose
scores were included, had treatment interrupted
(between 1 and 3 months) before neurodevelopmental
assessments were performed. One infant, on early ART,
was changed to second-line treatment at 6 months, (20
weeks before the GMDS) due to undisclosed treatment
interruption by parent. Clinicians assumed treatment
failure.
More infants on deferred ART compared with early ART
experienced hospital admissions (46 vs. 30%). The
deferred group stayed significantly longer in hospital
than the early group (mean 9.4 vs. 2.4 days; P< 0.01). At
assessment, head circumference was similar between the
comparison arms.
On the GMDS, all scores were lower in the deferred vs.
the early ART group (Table 2). General and Locomotor
scores were significantly lower: mean (SD)¼ 100.1
(13.8) vs. 106.3 (10.6), P¼ 0.02 and 88.9 (16.3) vs. 97.7
(12.5), P< 0.01, respectively. All scores in the early ART
arm were similar to those in both HIV-uninfected groups,
except for Locomotor wherein the HIV-exposed
uninfected arm performed better (Table 2).Copyright © Lippincott Williams & Wilkins. Unaut
24Discussion
In this study, HIV-infected infants receiving early
ART (<3 months old) scored higher on the GMDS
scales, particularly on the General and Locomotor
scores, compared to those on deferred ART. Children
with HIV who received early ART performed as well
as children without HIV except on the Locomotor
subscale.
Our findings show that children with HIV who start
ART earlier have better short-term neurodevelopmental
outcomes than infants for whom treatment is deferred.
The mean age starting ART in the deferred group was
31.4 weeks. Although this is early compared to many
studies describing neurodevelopmental outcomes
[3,4,12–15], even this delay is associated with poorer
outcomes. The mean time on ART in infants receiving
early ART compared to those on deferred ART was
significantly longer (18.7 vs. 40.9 weeks), potentially
influencing our findings.
Our study is limited by small sample sizes for the deferred
ART and uninfected groups. Given the trend to better
outcomes for hearing and speech, eye–hand coordination
and performance in the group on early ART, larger
sample sizes may have provided a more precise estimate.
Eight infants in the deferred group died before
assessment. Five of these infants had CDC stage C
disease. Had they lived to be assessed, they may have
lowered the scores in the deferred ART group further,
increasing the differences between arms. Literature has
established that neurodevelopmental outcomes in chil-
dren with AIDS-defining illness are worse than in those
without such diagnosis [7–8]. There was an imbalance in
primary language; there were more Xhosa-speaking
infants in the HIV-infected groups than in the uninfected
groups. This may indicate differences in cultural and
child-rearing practices but our experience of this age
group is that early childhood stimulation is similar in the
two language groups, as shown in the comparable results.
The study is further limited by the cross-sectional nature
of neurodevelopmental assessments. Also, viral loads and
CD4 cell counts were measured at varying times in
relation to neurodevelopmental assessment and ART
status, thus not being comparable. We, therefore, cannot
comment on the changes over time and response to
ART initiation.
The deferred arm had a higher incidence of illness and
hospitalization. The degree to which this may have
contributed to the neurodevelopmental delay is not clear.
More children in the deferred arm than the early arm
required hospitalization (46 vs. 30%) and the mean
hospital duration for those admitted was 9.4 vs. 2.4 days.
This confirms that early ART prevents morbidity, which
may have implications for large ART programmes in
developing countries.horized reproduction of this article is prohibited.
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Stellenbosch University https://scholar.sun.ac.zaThe GMDS has not been standardized for South African
children, but is widely used [16–18] and scores show
good correlation with British children from different race
and language groups [19]. Our results support the GMDS
as an appropriate tool in our setting. The mean scores on
all subscales between the unexposed uninfected and the
early ART groups were similar (Table 2). Although there
is a significant difference in the mean General and
Locomotor scores between the early therapy and deferred
therapy groups, the means are still within the normal
developmental range (within 1 SD) for the GMDS.
Strengths of this study include that this was performed in a
setting in which there is limited prenatal recreational drug
exposure. The study population is from a poor socio-
economic background, representative of infants accessing
public health system and the demographics of HIV
infection. Results should be generalizable to the relevant
South African population. The study is further strength-
ened by the inclusion of uninfected groups from similar
cultural and socioeconomic backgrounds, which con-
textualizes the information on performance on the
GMDS.
This study provides evidence of the neurodevelopmental
benefits of early ART. In infants tested at a median age of 11
months on the GMDS, those initiated at a mean of
8.4 weeks of age had significantly better Locomotor and
General scores than when ART was deferred, despite
careful monitoring and ready access to ART. It is plausible
that the true difference may be larger based on deaths
before assessments. In addition, we found little neurode-
velopmental difference between infants who received early
ART and infants who were uninfected with HIV. These
findings support the earliest possible diagnosis of HIVand
initiation of ART in infants. However, caution should be
exercised in extrapolating to long-term predictions.Acknowledgements
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Chapter 3 
Neurodevelopmental outcome of perinatally HIV-infected children on 
early limited or deferred continuous antiretroviral therapy at 5 years 
After our finding of improved neurodevelopmental outcome on early ART compared to 
the delayed ART arm in the Children with HIV Early antiRetroviral treatment (CHER) 
trial, we continued to follow the children through 4 more assessment time points until 
the age of 5 years, to investigate the effects of planned treatment interruption and 
cumulative toxicity. 
The Griffiths mental development scales (GMDS) were performed at 11, 20, 30, 42 and 60 
months [30, 32], and the Beery-Buktenica developmental tests for visual motor 
integration at 60 months.[33] Children who were HIV-exposed uninfected (HEU) and 
HIV-unexposed (HU) were enrolled for comparison. 
It was challenging to analyse and compare 5 groups, using longitudinal measures and 
consider missing data. Due to lack of South African norms, the statistical analysis was 
done using raw scores and quotients. We found no difference between the scoring 
systems, which contributes to existing knowledge of the performance of South African 
children on the GMDS. 
We found that poorer locomotor and general Griffiths scores at 11 and 20 months of age, 
in the delayed ART arm, had resolved by 42 months. Neurodevelopmental outcomes at 
five years in HIV+ children on early time-limited ART were similar to uninfected controls. 
However HIV+ children scored significantly lower on visual perception test than 
uninfected controls.[33] This was despite viral suppression and suggested that HIV 
adversely affected visual perception regardless of ART strategy. 
Our findings suggest that limited ART interruption in children perinatally infected with 
HIV who started ART < 12 weeks of age while asymptomatic, did not negatively affect 
their neurodevelopmental outcomes at five years, although there was subtle evidence of 
developmental delay during treatment interruption. This supports clinical, 
immunological and virological findings from the larger CHER cohort that early 
time-limited ART appears safe [27].  
This publication was 9th in the top 10 most popular articles in JIAS in 2018 with 2927 
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Abstract
Introduction: Early antiretroviral therapy (ART) has improved neurodevelopmental outcomes of HIV-infected (HIV-positive)
children; however, little is known about the longer term outcomes in infants commencing early ART or whether temporary ART
interruption might have long-term consequences. In the children with HIV early antiretroviral treatment (CHER) trial, HIV-
infected infants ≤12 weeks of age with CD4 ≥25% were randomized to deferred ART (ART-Def); immediate time-limited ART
for 40 weeks (ART-40W) or 96 weeks (ART-96W). ART was restarted in the time-limited arms for immunologic/clinical progres-
sion. Our objective was to compare the neurodevelopmental profiles in all three arms of Cape Town CHER participants.
Methods: A prospective, longitudinal observational study was used. The Griffiths mental development scales (GMDS), which
includes six subscales and a global score, were performed at 11, 20, 30, 42 and 60 months, and the Beery-Buktenica develop-
mental tests for visual motor integration at 60 months. HIV-exposed uninfected (HEU) and HIV-unexposed (HU) children were
enrolled for comparison. Mixed model repeated measures were used to compare groups over time, using quotients derived
from standardized British norms.
Results: In this study, 28 ART-Def, 35 ART-40W, 33 ART-96W CHER children, and 34 HEU and 39 HU controls were
enrolled. GMDS scores over five years were similar between the five groups in all subscales except locomotor and general
Griffiths (interaction p < 0.001 and p = 0.02 respectively), driven by early lower scores in the ART-Def arm. At 60 months,
scores for all groups were similar in each GMDS scale. However, Beery visual perception scores were significantly lower in
HIV-infected children (mean standard scores: 75.8 ART-Def, 79.8 ART-40W, 75.9 ART-96W) versus 84.4 in HEU and 90.5 in
HU (p < 0.01)).
Conclusions: Early locomotor delay in the ART-Def arm resolved by five years. Neurodevelopmental outcomes at five years in
HIV-infected children on early time-limited ART were similar to uninfected controls, apart from visual perception where HIV-
infected children scored lower. Poorer visual perception performance warrants further investigation.
Keywords: HIV care continuum; Children; ARV; CHER trial; Early time-limited antiretroviral therapy; Neurodevelopment;
Treatment interruption; Griffiths mental development scales; Visual perception
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1 | INTRODUCTION
HIV encephalopathy, a common finding in perinatally HIV-
infected children, has decreased since the introduction of
combination antiretroviral therapy (ART) [1]. Other neurode-
velopmental deficits despite ART remain a concern. Although
early viral suppression is beneficial for neurodevelopmental
outcomes [2-5], the long-term outcomes of children after early
ART are unclear and may be compromised by cumulative toxi-
city or waning adherence. Early treatment with planned inter-
ruptions after early virological suppression is a possible
solution.
The Children with HIV Early Antiretroviral (CHER) trial
conducted in South Africa (2005 to 2011) compared early
time-limited ART with deferred ART in asymptomatic HIV-
infected infants [6,7]. HIV-infected infants with CD4 ≥25%




were randomized to one of three strategies: (i) ART deferred
until indicated (ART-Def), (ii) early limited ART for 40 weeks
(ART-40W) and (iii) early limited ART for 96 weeks
(ART-96W). Continuous ART was initiated (in ART-Def) and
re-initiated (in ART-40W and ART-96W) if CD4% declined
<25% in the first year of life and <20% thereafter, or for pro-
tocol-defined severe stage B or stage C clinical disease. After
a median of 4.8 years, the superiority of early time-limited
over deferred continuous ART was confirmed [6].
A neurodevelopmental sub-study of CHER found signifi-
cantly better locomotor and general development scores at
11 months for early ART, with children in ART-Def scoring
significantly lower than the combined early ART arms. How-
ever, the early treatment arms had not yet interrupted ART
[8]. These neurodevelopmental outcomes contrast with older
children from the PREDICT study which showed no difference
between early versus deferred ART in children with CD4 15%
to 24%. In PREDICT, HIV-infected children performed worse
than uninfected controls [9].
Here, we present the neurodevelopmental profiles over five
years of this CHER sub-study which includes data from the
treatment interruption phase. We hypothesized: firstly that
the early treatment arms would do better than the deferred
arm, and that the improved neurodevelopmental outcomes
seen at 11 months in the early treatment arms would persist
despite time off therapy, and be similar to HIV-uninfected con-
trols; secondly that within the early treatment groups, care-
fully guided ART interruption would not affect
neurodevelopmental outcomes.
2 | METHODS
2.1 | Study Design and Participants:
This was a prospective, longitudinal observational sub-study of
CHER trial, conducted at the Cape Town site only, between
2006 and 2013. Of 411 infants enrolled onto CHER with CD4
≥25%, 119 HIV-infected infants in Cape Town were available,
along with 42 perinatally HIV-exposed uninfected (HEU) and 42
HIV-unexposed (HU) controls from a concurrent linked vaccine
study [10]. Inclusion criteria for the sub-study were: birthweight
>2000 g, normal neurological examination at a clinical visit near
three months of age, no dysmorphic syndromes or central ner-
vous system (CNS) insults, for example foetal alcohol exposure,
birth asphyxia or metabolic abnormalities. HEU and HU controls
were enrolled at the same time to provide a reference group
for interpreting neurodevelopmental scores within the socio-
economic and cultural context. HEU infants also controlled for
ART exposure to prevent mother to child transmission (PMTCT)
and circumstances surrounding growing up with an HIV-
infected mother. Mothers or legal guardians were approached
from 2006 during a CHER or Vaccine study visit. Written con-
sent was obtained in their preferred language. Participants who
missed early enrolment were included at a later visit. The Stel-
lenbosch University Health Research Ethics Committee
approved the study, registration: N05/05/092. Due to attrition
of controls, additional five year old Xhosa children (7 HEU, 3
HU) were enrolled from the original source communities in
2012. Eligibility criteria included documented evidence of
mother’s HIV-negative status at birth, child’s HIV-1 antibody
test negative, birthweight >2000 g, no history of CNS insults,
being clinically healthy with normal medical history and general
examination performed by a study doctor.
2.2 | Neurodevelopmental Assessments:
The Griffiths Mental Development Scales (GMDS) were per-
formed at a CHER study visit. The baby scales (0 to 2 years)
were used at 11 and 20 months [11] and the extended revised
version (2 to 8 years) at 30, 42 and 60 months [12]. The GMDS
assesses neurodevelopment on six subscales: locomotor, per-
sonal-social, hearing and language, eye and hand coordination,
and performance (visuospatial skills including speed and preci-
sion), adding practical reasoning after 24 months. A general
Griffiths score, an average of the subscales, is also obtained.
One of the four GMDS-trained paediatricians conducted the
assessments, assisted by a GMDS-trained translator using stan-
dardized translations, all blinded to treatment arm allocation.
One paediatrician conducted only four assessments, all at
11 months. The other three assessed at all time points. At the
beginning of each age time point, the paediatricians assessed a
child together and marked independently, and compared scores
and discussed discrepancies afterwards. This was repeated on
different children until scoring was similar. The GMDS provides
standardized norms from typical British children. Quotients
were used to compare performance at different time points. The
0 to 2 year scale provides quotients from raw scores, and 2 to
8 year scales provide percentiles and z-scores. For 2 to 5 year
olds, we converted raw scores into age equivalents (from the
standardized scores 50th percentiles) and calculated a quotient
as a percentage of the child’s chronological age, for the sub-
scales and general Griffiths. At 60 months of age, the Beery-
Buktenica developmental tests of visual motor integration
(Beery-VMI), visual perception and motor coordination (sixth
edition) were administered [13]. The Beery-VMI measures the
ability to coordinate visual perceptual and motor skills by copy-
ing geometric forms. Visual perception requires the child to iden-
tify matching forms, and motor coordination involves drawing
the forms by connecting dots and staying within paths provided,
abilities that are not assessed in the GMDS. Standard scores
were calculated from raw scores using USA norms. Neurodevel-
opmental scores are standardized with a mean (SD) quotient or
standard score of 100 (15), scores of 90 to 109 are considered
average and <70 as intellectual impaired/delayed [11,13].
Neurological examination and head circumference measure-
ment were performed at each visit and the Child Behavior
Checklist completed at 20, 42 and 60 months (reported else-
where) [14]. Parents or caregivers received a written report
after each assessment with advice for stimulating weaker areas
of development. Children with suspected sensory deficits or sig-
nificant developmental delay were referred to appropriate diag-
nostic and therapeutic services. We included assessments
previously reported at 11 months [8] to better present the lon-
gitudinal developmental profile over five years. Primary end-
points were neurodevelopmental scores at each assessment.
2.3 | Clinical data
On CHER, HIV-infected participants had regular clinical visits:
every 4 weeks until week 24, every 8 weeks until week 48
and then every 12 weeks. Assessments included: physical
examination, ART adherence and management of any illnesses




or adverse events, and T-cell subsets were done. HIV-RNA
viral loads (VL) were only performed if treatment failure was
suspected until November 2009, thereafter VL were per-
formed 6 monthly. A blinded independent clinical endpoint
review committee adjudicated CDC severe stage B and C
events and HIV encephalopathy diagnosis without knowledge
of CD4 values, ART status or treatment group [6,7]. HEU and
HU children had three monthly clinical assessments for
18 months and then annually thereafter [10].
Demographic and clinical information were obtained from the
CHER database. In HIV-infected participants, viral load (VL) and
CD4 values from baseline and within six months of the
60 months assessment were used, together with baseline CMV
viraemia [15]. HIV-negative status of controls on the vaccine
trial was confirmed between 16 and 28 weeks of age [10].
2.4 | Statistical analysis
We used Statistica version 13 (software.dell.com. Dell Inc.
2015). The primary analysis compared neurodevelopmental
quotients over time in five groups (three HIV-infected: ART-
Def, ART-40W and ART-96W, and two uninfected: HEU, HU)
using linear mixed models with group and time as categorical
fixed effects, and participants as random effect. We opted for
parsimony and therefore compound symmetry was used. Sam-
ple size calculations were based on predicted neurodevelop-
mental outcomes, which we expected to be larger. To detect
an average effect size of 7.5 (half SD on GMDS and Beery
tests) at 5% significance level, 30 per group would provide
90% power and 25 per group 80% power.
Due to concerns about using British norms for GMDS out-
comes, we conducted post-hoc analyses using age-adjusted
raw scores. Comparison of scores over 5 years was not possi-
ble, due to differences in raw score calculation <2 years and
>2 years. We therefore compared, time points 1 to 2 and time
points 3, 4 and 5 separately.
Summary statistics for background information were com-
pared using chi-squared test for categorical variables and one-
way analysis of variance (ANOVA) for continuous measures.
Mean (SD) or median [IQR] were reported, depending on nor-
mality and homogeneity of variance.
Additional analysis was performed combining the three
HIV-infected arms. Spearman correlations were determined
between neurodevelopmental outcomes at 60 months and the
following: (i) age at starting ART, (ii) time on ART, (iii) time to
VL suppression (age at first VL <400 copies/ml) and (iv) CD4
values at enrolment onto CHER. A 95% confidence interval
was calculated and significance established at p < 0.05. For
variables in the mixed model analysis, the Fisher least signifi-
cant difference was used.
3 | RESULTS
3.1 | Participants
Ninety-six HIV-infected infants of the 119 CHER trial partici-
pants in Cape Town were enrolled in the neurodevelopmental
sub-study: 28 ART-Def (excluded two refusals and eight
deaths before 11 months), 35 ART-40W (excluded four refu-
sals and two to foetal alcohol exposure (FAE)) and 33 ART-
96W (excluded four refusals and one glutaric-aciduria, one
FAE, one non-adherence to CHER protocol); 63 of 84 unin-
fected controls from the vaccine study were enrolled; and 10
additional controls at 60 months (total enrolled: 34 HEU, 39
HU). One infant in ART-96W died at 21 months (disseminated
tuberculosis) and one HU child died at 48.5 months (motor
vehicle accident). At 60 months, retention in arms was 26/28
(93%) in ART-Def, 29/35(83%) ART-40W and 23/33(70%)
ART-96W, and retention in controls from baseline was 15/27
(56%) in HEU and 25/36(69%) HU. For details on participants
enrolled and assessed at each time point, see Figure S1.
3.2 | Participant Characteristics
There were more boys in the controls than the HIV-infected
groups (Table 1). Birthweight was similar between groups. There
was variability in the mode of delivery, with vaginal deliveries
ranging from 68% (HEU) to 86% (ART-40W). For PMTCT, most
mothers and babies received nevirapine and zidovudine. Three
HIV-positive mother-child dyads had no PMTCT. The mean age of
mothers at birth of HEU infants was slightly older than the other
groups (30.9 years vs. means between 27 and 28 years).
Maternal education level was similar between groups. Almost all
HIV-infected infants, but only 36% of HU infants, were Xhosa-
speaking. In the HIV-infected groups, baseline CD4 parameters
and mean VL were similar while the proportion with CMV
viraemia at baseline ranged from 13% to 29%.
Of HIV-infected participants enrolled, those developing
CDC stage severe B or stage C diagnosis were 10/28(36%) in
ART-Def, 15/35(43%) in ART 40W and 11/33(33%) in ART
96W. These included HIV encephalopathy in four (14%) ART-
Def (diagnosed at 5, 9, 31 and 61 months), five (14%) ART-
40W infants (at 19, 20, 21, 24 and 31 months) and two (6%)
ART-96W (at 10 and 31 months). Table 2 further describes
characteristics of HIV-infected participants.
3.3 | Neurodevelopmental assessments and
outcomes:
In general, mean GMDS scores declined over time in all sub-
scales and in all groups, including controls. The most signifi-
cant differences in longitudinal profile between groups were
in the locomotor subscale (p < 0.001) and general Griffiths
scale (p = 0.02), driven by initial lower scores in ART-Def
arm at 11 and 20 months. The control groups had higher
scores than the HIV-infected arms at the first three assess-
ments in most subscales. However, scores for all groups were
similar at 42 and 60 months, with mean quotient for each
group ranging from 93.2 to 98.7 for the locomotor subscale
and from 81.8 to 84.7 for general Griffiths (Figure 1 and
Table 3). Not all children were assessed at each time point
due to missed visits or withdrawal, mainly relocation to rural
areas.
Results for raw scores (controlling for age) were similar to
those for quotients. Differences in developmental profile
between groups in the locomotor subscale were confirmed
between 30, 42 and 60 months (interactive p = 0.009), but
the general Griffiths was not as robust (interactive = p 0.1).
The raw scores also confirmed significant differences in pair-
wise comparisons between groups in early assessments, and
no difference between arms at 5 years, observed for compar-
ing the quotients. Analysis of raw scores in other Subscales




confirmed no difference in profiles. (See Supplementary
material Tables S3, S4 and S5).
For visual perception at 60 months, the HIV-infected
groups scored 5 to 9 points lower than HEU group and 10 to
14 points lower than HU, but Beery-VMI and motor coordina-
tion were similar (Table 4). During assessments, no children
were suspected of having visual problems.
3.4 | Antiretroviral therapy and responses:
Children on early ART began first-line therapy (zidovudine, lami-
vudine and lopinavir/ritonavir) at a meanSD of 1.3  0.5
months (ART-40W) and 1.5  0.5 months (ART-96W) com-
pared to ART-Def (6.8  3.5 months; range 3.9 to 17.7)
(Table 2). For ART-40W, of 35 enrolled, two left the study
before 40 weeks and 4 met criteria for not interrupting; 29/33
(88%) interrupted at a mean age of 11.4 months for a median of
7.0 [IQR 5.0 to 11.0] months. At 60 months, one was still off
ART. For ART-96W, of 33 enrolled, three left the study, one died
before 96 weeks and nine met criteria for not interrupting; 20/
29(69%) interrupted treatment at a mean age of 24.5 months
for a median of 8.0 [IQR 7.0 to 36.0] months (one withdrew
before restarting). At 60 months, 14 had restarted and five
were still off ART. The meanSD cumulative time on ART until
60 months was similar among ART-40W and ART-96W and
shorter than ART-Def. One child changed to second line ART at
2 years due to CD4 <20% (in ART-40W). Table 2 describes the
proportion of participants off ART of those assessed at each
assessment.
3.5 | Clinical measures at five years
The proportion of infants with severe CDC stage B or C and
HIV encephalopathy of those assessed at 5 years is described
in Table 2. At 60 months, 92% in ART-Def, 97% in ART-40W
and 74% in ART-96W had VL <400 copies/ml. Mean CD4
parameters and mean WHO height-for-age z-scores were sim-
ilar in the groups.
3.6 | Correlations between clinical parameters and
neurodevelopment at five years
Combining all HIV-infected infants, correlations were weak
between neurodevelopmental outcomes at five years and age
starting ART, baseline CD4 count, time on ART and time to
first VL suppression (Spearman r between 0.19 and 0.08).
Table 1. Demographic data and clinical characteristics of all study participants
HIV infected Uninfected
p valueART-Def (n = 28) ART-40W (n = 35) ART-96W (n = 33) HEU (n = 34) HU (n = 39)
Gender: Male 11 (39%) 15 (43%) 13 (40%) 19 (56%) 23 (59%) 0.29*
Birthweight, g, mean (SD) 3036 (407) 3096 (445) 2912 (411) 3090 (513) 3127 (561) 0.36*
Delivery
NVD n (%) 20 (71%) 30 (86%) 28 (85%) 23 (68%) 31 (84%)
C/S n (%) 8 (29%) 5 (14%) 5 (15%) 11 (32%) 6 (16%) 0.23*
Unknown 2
PMTCT exposure
Mother n (%) 27 (96%) 31 (89%) 31 (84%) 29 (85%) – 0.14#
Child n (%) 25 (89%) 32 (91%) 32 (97%) 29 (85%) – 0.15#
No PMTCT n 0 2 1 0
Unknown n 0 0 0 5 (15%)
Mother’s age at birth (years) mean (SD) 27.2 (5.1) 27 (4.4) 27.2 (5.8) 30.9 (14.1) 28 (7.2) 0.26*
Mother’s education mean (SD)
(highest grade attended)
10.0 (2.1) 9.4 (2.3) 9.4 (2.7) 9.9 (2.4) 9.8 (2.0) 0.70*
Language
Xhosa n (%) 27 (96%) 32 (91%) 30 (91%) 28 (88%) 14 (36%) <0.001*
Afrikaans n 1 3 3 4 25
English n 2
Mean (SD) at baseline
CD4 count (cells/ll) 1781 (672) 2082 (968) 2076 (1151) – – 0.39§
CD4% 35.8 (8.4) 35.5 (8.6) 34.5 (8.6) 0.81§
Viral load at baseline copies/ml
Mean (SD)
598,504 (243,254) 528,435 (250,021) 593,933 (244,958) – – 0.38§
CMV PCR at baseline n (%)
>25 copies/ml
5/25 (20%) 8/28 (29%) 4/30 (13%) – – 0.35§
Treatment groups: ART-Def: ART deferred until symptomatic, ART-40W: early ART until 40 weeks then planned interruption, ART-96W: early
ART until 96 weeks then planned interruption. Control groups: HEU: HIV-exposed uninfected, HU: HIV-unexposed. Chi-square for categorical vari-
ables and ANOVAs for continuous variables
p values: *between 5 groups, #between 4 groups, §between 3 groups.




Higher baseline CD4% correlated significantly with lower
locomotor motor scores (r 0.23; p = 0.03) and marginally
with Beery-VMI (r 0.2; p = 0.06) and motor coordination
(r 0.1; p = 0.06). (Supplementary Material Tables S1 and
S2).
4 | DISCUSSION
Through serial testing, we demonstrated poorer locomotor
and general Griffiths scores in ART-Def at 11 and 20 months
of age, which had resolved by 42 months and was maintained
at five years. The limited differences between groups over
time on personal-social, language, eye and hand coordination,
performance and practical reasoning GMDS subscales is
encouraging. Our findings suggest that limited ART interrup-
tion under careful clinical guidance in asymptomatic children
starting ART ≤12 weeks of age did not negatively affect their
neurodevelopmental outcomes at five years. This supports
clinical, immunological and virological findings from the larger
CHER cohort that early time-limited ART appears safe [6].
At 11 months, neurodevelopmental scores of ART-Def were
generally lower than the other arms. Our longer term findings pro-
vide new evidence that catch-up/recovery is possible after delayed
ART initiation. However, eight early deaths in ART-Def prior to
GMDS assessments may have contributed to a survivor effect.
Our finding that all HIV-infected arms had visual perceptual
scores significantly below HU children at 5 years, is concern-
ing. Similarly, two HIV-infected arms (ART-Def and ART-40W)
also scored significantly below HEU children. This was despite
viral suppression and suggests that HIV adversely affects
visual perception regardless of ART strategy. However, cultural
differences in early childhood stimulation may have influenced
these findings as there were more Afrikaans-speaking children
Table 2. Descriptive characteristics of HIV-infected participants
Antiretroviral therapy for all enrolled participants
ART-Def ART-40W ART-96W
p valueN = 28 N = 35 N = 33
Age at ART initiation, months mean (SD) 6.8 (3.5) 1.3 (0.5) 1.5 (0.5) <0.001
Treatment interruption: n (%) Not applicable 29/35 (88%) 20/33 (61%) 0.04
Median [IQR] time interrupted (months) 7 [5 to 11]a 8 [7 to 36]b
Assessments at each time in time-limited treatment groups and proportion off ART
ART 40-W ART-96W
Assessment age Number assessed Number interrupted (%) Number assessed Number interrupted (%)
11 months 34 0 32 0
20 months 33 14 (42%) 29 0
30 months 32 5 (16%) 28 16 (57%)
42 months 29 1 (4%) 26 6 (23%)
60 months 29 1 (4%) 23 5 (22%)
Antiretroviral therapy and clinical parameters at five years for those assessed at 5 years
ART-Def ART-40W ART-96W p value
N = 26 N = 29 N = 23
Cumulative time on ART at 5 years.
assessment, (months) mean (SD)
54.6 (3.6) 49.4 (12) 48.1 (14.5) <0.001
Severe stage B/C diagnosis, n (%) 9 (35%) 13 (45%) 6 (26%) >0.2c
HIV encephalopathy, n (%) 4 (15%) 4 (14%) 2 (9%) >0.5 c
CD4 count mean (SD) 1080 (363) 1192 (492) 1032 (541) 0.45
CD4% mean (SD) 36.6 (5.8) 34.4 (6.9) 33.1 (8.2) 0.22
VL <400 copies/ml 24/26 (92%) 28/29 (97%)a 17/23 (74%)b
WHO height-for-age z-score mean (SD) 0.64 (1.0) 0.90 (1.2) 0.83 (0.8) 0.59
WHO weight-for-age z-score mean (SD) 0.09 (1.1) 0.05 (1.1) 0.26 (0.8) 0.44
Treatment groups: ART-Def: ART deferred until symptomatic, ART-40W: early ART until 40 weeks then planned interruption, ART-96W: early
ART until 96 weeks then planned interruption.
aIncludes 1 who had not yet restarted ART at 60 months.
bIncludes 5 who had not yet restarted ART at 60 months and one left study before restarting.
cPairwise chi-square comparison between groups.




Figure 1. Comparison of Griffiths scales of mental development scores over time per arm. LS means, Type III decomposition, Vertical bars denote
0.95 confidence intervals, interaction p-values. X Axis: Mean age at time points: 1 = 11 months, 2 = 20 months, 3 = 30 months, 4 = 42 months,
5 = 60 months. Note: Lines connecting scores added for visual clarity and do not imply participants identical at each time point.


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































in the HU group. This observation requires further investiga-
tion as visual perception may be the underlying cause of defi-
cits found in later childhood. Visual perception involves
recognition and discrimination of visual shapes and objects.
This process involves the cognitive components and executive
tasks of visual attention, memory, discrimination and imagery.
Perceptual identification is processed by the ventral stream
pathway [16], which may be vulnerable to HIV. Deficits may
impair reading, writing and mathematics achievement [17].
Deficits in visual spatial organization, processing and working
memory have been described in HIV-infected children, even in
the context of normal cognitive development, higher CD4
counts or clinical stability [18-21]. Interestingly, there was no
difference between groups on the Beery-VMI and motor coor-
dination tests. Abnormal visual perception in children with
normal Beery-VMI scores has been described [17]. It is impor-
tant to consider that the Beery-VMI may not be sensitive
enough to measure the specific visual perceptual deficit
caused by HIV in young children.
It is possible that ART interruption at 96 weeks may be bet-
ter than at 40 weeks, as suggested in the main results paper
[6]. There was more HIV encephalopathy in ART-Def and ART-
40W compared to ART-96W, and ART-40W also had more
CDC severe stage B and stage C diagnoses than the other
arms, with the increase occurring largely between the 11 and
18 months’ assessments during treatment interruption. On the
other hand, fewer children underwent interruption or had base-
line CMV viraemia in ART-96W. Interpreting the effects of
treatment interruption is difficult as some children randomized
to ART-40W or ART-96W were not interrupted, there was a
wide range of time off ART, and ART-Def had a longer mean
time on ART than the early time-limited arms.
On secondary analysis there were no significant correlations
between neurodevelopmental outcome at five years and the
following parameters: age at starting ART, time to first viral
suppression and time on ART. Interestingly, a higher CD4% at
baseline significantly correlated with lower locomotor scores
(Spearman r of 0.23) and marginally correlated with lower
Beery-VMI and motor coordination scores. Although counter-
intuitive, we considered a number of explanations. A higher
CD4% in ART-Def may have led to a longer period of obser-
vation prior to ART initiation; those on time-limited ART
(ART-40W and ART-96W) may have been more likely to inter-
rupt ART than in those who reached an endpoint prior to
interruption so would have remained on continuous ART. This
issue requires further exploration.
It is interesting to note that on the locomotor subscale, the
mean quotients decreased over time in both uninfected
groups while increasing in HIV-infected arms. Similar decline
over time was noted in most other subscales. The ART-Def
and ART-40W arms may be demonstrating catch up due to
longer time on suppressive ART from an early age. However,
this should be interpreted with caution due to small numbers
in infected arms and the enrolment of additional controls at
five years.
The GMDS may be insufficiently sensitive to discriminate
between the groups at five years, thus creating an impression
of “catch up” in the infected groups. Alternatively, the effects
of poverty and deprivation on early childhood development

























































































































































































































































































































































































































































































































































































































































The decline in all GMDS scores except for the personal-
social subscale most likely reflects the application of British
norms [11,12] to South African children from impoverished
environments, and emphasizes the importance of having unin-
fected controls from the same communities. The GMDS has
Xhosa and Afrikaans translations, is widely used in South
Africa and thought to be culturally fair [24-26]. However, cau-
tion should be used when interpreting these results for clinical
purposes. In a post-hoc analysis, the longitudinal profiles of
age-adjusted raw scores supports our findings when using
quotients for locomotor; however, there is a weaker associa-
tion with general Griffiths and similar scores between groups
at five years. We did not see a decline in scores over time for
raw scores. (See supplemental material Tables S4 and S5)
The strengths of the study are that this is a relatively cohe-
sive sample recruited from communities with minimal prenatal
substance abuse and includes uninfected children from the
same communities.. The similar demographic and clinical char-
acteristics in the HIV-infected arms reflect successful random-
ization of this sub-study within the main trial. A further
strength is the longitudinal nature of assessments, despite rel-
atively small numbers and some attrition.
4.1 | Limitations
Our results should be considered within the context of small
numbers and variability between groups. The original sample
size for this study was calculated assuming a larger difference
in neurodevelopmental scores between groups and larger
group numbers. Some missed visits and attrition further
reduced sample sizes. An inherent bias was that controls had
less clinical contact time than HIV-infected children as they
had no medication visits, and additional controls were added
at five years. Although there were more Afrikaans-speaking
HU participants, they were from similar socio-economic back-
grounds to the Xhosa-speaking participants with similar neu-
rodevelopmental trajectories. However, we cannot rule out
the cultural effects of early childhood rearing practices which
may have influenced some comparisons. While we acknowl-
edge that illnesses and maternal depression are important
influences on early childhood development, we exclude the
effects of hospitalizations and maternal depression due to
small sample sizes relative to the number of arms and assess-
ment time points. We have previously described the high inci-
dence of maternal depression and effects of maternal trauma
in this cohort [14,27]. As we did not determine whether the
HIV infection occurred in utero or perinatally, each arm had
potential heterogeneity, making further interpretation of ART
interruption difficult.
Nevertheless, we found that early ART improved neurode-
velopmental outcomes. Planned treatment interruption
appeared safe in children who suppressed early. This is reas-
suring for situations where ART interruption is unavoidable,
for example lack of supplies or social/political disruption.
All HIV-infected children should be assessed for visual per-
ceptual deficits and referred for intervention as needed, to
improve educational outcomes.
5 | CONCLUSIONS
HIV-infected children on ART-Def arm had locomotor delay at
younger ages, which recovered by 5 years. For children with
perinatal HIV infection, the neurodevelopmental outcomes at
five years of asymptomatic children with preserved CD4 T-cell
percentages and receiving early but limited ART under strict











n = 28 p value
Visual motor integration (VMI)
Mean quotient SD 89.7  9.0 89.0  7.3 90.3  11.7 88.0  10.3 92.7  10.5 0.89
95% CI (86.1 to 93.3) (86.2 to 91.8) (85.2 to 95.4) (83.3 to 92.7) (88.6 to 96.7)
Visual perception
Mean quotient SD 75.8  15.9a 79.8  14.7a 75.9  13.5 84.4  13.5b 90.5  9.3 <0.01
95% CI (69.2 to 82.3) (74.1 to 85.5) (69.9 to 81.9) (77.9 to 90.9) (86.9 to 94.1)
Motor coordination
Mean quotient SD 94.110.6 93.68.4 96.57.3 93.912.3 92.912.3 0.8
95% CI (89.8 to 98.3) (90.4 to 96.8) (93.3 to 99.7) (88.3 to 99.5) (88.1 to 97.7)
p-values for pairwise comparisons between groups for Beery-Buktenica developmental tests
Assessment 1 versus 2 1 versus 3 1 versus 4 1 versus 5 2 versus 3 2 versus 4 2 versus 5 3 versus 4 3 versus 5 4 versus 5
Visual motor
integration
0.78 0.83 0.56 0.26 0.62 0.73 0.15 0.44 0.39 0.1
Visual perception 0.28 0.98 0.04* <0.001* 0.31 0.26 0.004* 0.05* <0.001* 0.13
Motor coordination 0.87 0.42 0.96 0.68 0.33 0.92 0.79 0.41 0.23 0.74
Treatment groups: ART-Def: ART deferred until symptomatic, ART-40W: early ART until 40 weeks then planned interruption, ART-96W: early
ART until 96 weeks then planned interruption. Control groups: HEU: HIV-exposed uninfected, HU: HIV-unexposed.
a1 participant and b2 participants did not complete the test. *Significant differences.




clinical guidance, is similar to HIV-uninfected neighbourhood
controls. However, poorer visual perception in HIV-infected chil-
dren, irrespective of ARTstrategy, requires further exploration.
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Correlations between clinical parameters and neurodevelopment at 5 years: 
Age starting ART and the General Griffiths quotient at 5 years: Spearman r= -0·03  
Time spent on ART and the General Griffiths quotient at 5 years: Spearman r=-0·13 
Time to first HIV viral suppression and neurodevelopmental scores at 5 years: 
Spearman r ranged from -0·12 to 0·07 (table 1) 
Baseline CD4 percentage and count and neurodevelopmental scores at 5 years: 
Spearman r ranged from -0·23 to 0·08 (table 2) 
Table 1: Correlation between time to first viral suppression (age at first 
viral load <400 copies/ml) and neurodevelopmental scores at 5 years: 
Spearman r p value 
Griffiths Mental Development Scales: 
Locomotor 0.02 0.86 
Personal-Social -0.1 0.4 
Language -0.04 0.74 
Eye& Hand Coordination 0.02 0.86 
Performance -0.12 0.29 
Practical Reasoning 0.05 0.65 
General Griffiths -0.03 0.82 
Beery-Buktenica Tests: 
Visual Motor Integration -0.06 0.6 
Visual Perception 0.04 0.75 
Motor Coordination 0.07 0.55 
Table 2: Correlation between baseline CD4 values  and neurodevelopmental 
scores at 5 years 
CD4 count CD4 % 
Spearman r p value Spearman r   p value 
Griffiths Mental 
Development Scales: 
Locomotor -0.19 0.08 -0.23 0.03 
Personal-Social 0.00 0.99 0.08 0.48 
Language 0.08 0.48 -0.18 0.11 
Eye& Hand Coordination -0.08 0.48 -0.07 0.52 
Performance -0.03 0.75 -0.10 0.34 
Practical Reasoning -0.09 0.41 -0.03 0.79 
General Griffiths -0.13 0.24 -0.16 0.14 
Beery-Buktenica Tests: 
Visual Motor Integration -0.13 0.25 -0.20 0.06 
Visual Perception -0.19 0.08 -0.07 0.53 
Motor Coordination -0.10 0.37 -0.21 0.06 
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Comparison of statistical analysis using Quotients from UK standardised norms 
and raw scores. 
Raw scores were adjusted for age at each time point. 
The raw scores derived from the Griffiths 0-2 year old (baby scales) are different to the 
Griffiths 2-5 year old (Extended Revised version) and it was not possible to compare 
raw scores over 5 time points.  (Study objective was to compare neurodevelopmental 
profiles over 5 year of 5 groups of children). Analysis or raw scores was restricted to 
comparing the profile in the arms in two sections between time points 1-2 and between 
time points 3, 4, 5. 
Table 3: Comparison of statistical analysis using Quotients from British standardised norms and 
raw scores. Linear mixed model with group and time as categorical fixed effects: interaction p 
value 
Statistical method used Raw scores with age as covariate Quotients 
Time points included 1-2 3,4,5 1,2,3,4,5 
General Griffiths 0.84 0.10 0.02* 
Locomotor 0.3 0.009 <0.001* 
Personal-Social 0.37 0.67 0.25 
language 0.15 0.67 0.88 
Eye& Hand Co-ordination 0.40 0.46 0.09 
Performance 0.40 0.88 0.21 
Practical Reasoning n/a 0.41 §0.51
§ only tested at 3 ,4 ,5
For the General Griffiths raw scores, the differences in neurodevelopmental trajectories 
in the arms is no longer significant. 
The General Griffiths raw score is calculated differently at 1-2 (total of subtest raw 
scores) and 3, 4, 5 (average of subtest raw scores).  
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Table 4: Pairwise comparisons between groups of means for age-adjusted raw scores and 














































1  Raw 0.12 0.07 0.01* 0.04* 0.75 0.23 0.57 0.37 0.82 0.47 
Quotient 0.03* 0.02* 0.008* 0.006* 0.92 0.52 0.59 0.59 0.67 0.88 
2  Raw 0.51 0.10 0.00* 0.14 0.27 0.01* 0.36 0.14 0.9 0.1 
Quotient 0.35 0.12 0.001* 0.05* 0.5 0.01* 0.28 0.05* 0.71 0.1 
3  Raw 0.47 0.02* 0.85 0.33 0.01* 0.43 0.02* 0.15 
Quotient 0.8 0.78 0.37 0.005* 0.58 0.25 0.001* 0.51 0.01* 0.09 
4 Raw 0.90 0.38 0.48 0.11 0.44 0.55 0.13 0.89 0.49 0.42 
Quotient 0.97 0.47 0.41 0.14 0.44 0.38 0.12 0.89 0.47 0.58 
5 Raw 0.06 0.26 0.62 0.70 0.7 0.18 0.11 0.55 0.43 0.88 
Quotient 0.24 0.45 0.45 0.78 0.71 0.72 0.35 1 0.61 0.61 
For the pairwise comparisons of General Griffiths score, there are discrepancies 
between the raw scores and quotients.  Using raw scores there is no difference between 
infected groups, but the difference between infected and uninfected groups persist.  
This is likely due to the effect of locomotor delay being diluted out in the general score.   
The age adjustment may also have had an effect – quotients are calculated in one month 
periods – age adjustments were performed on actual age and decimals of months. (i.e 
children with ages 11,2; 11,4; 11,8 months will all have the same quotient but raw 
scores are age adjusted) (table 5) 
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Table 5: Pairwise comparisons between groups of means for age-adjusted raw scores and 














































1 Raw 0.03* 0.02* <0.001* <0.001* 0.8 <0.001* 0.09 0.01* 0.15 0.16 
Quotient 0.02* 0.03* <0.001* <0.001* 0.9 0.03* 0.15 0.03* 0.14 0.39 
2 Raw 0.47 0.04* 0.02 0.13 0.14 0.06 0.37 0.54 0.63 0.28 
Quotient 0.26 0.03* 0.001* 0.003* 0.24 0.01* 0.04* 0.12 0.41 0.4 
3  raw 0.87 0.71 0.18 0.04* 0.58 0.21 0.04* 0.09 0.01* 0.56 
Quotient 0.61 0.97 0.03* 0.001* 0.63 0.07 0.004* 0.03* 0.001* 0.47 
4 raw 0.52 0.93 0.89 0.51 0.58 0.45 0.18 0.82 0.46 0.63 
Quotient 0.56 0.82 0.77 0.62 0.73 0.4 0.27 0.61 0.47 0.87 
5  Raw 0.35 0.57 0.88 0.06 0.73 0.45 0.33 0.68 0.21 0.1 
Quotient 0.44 0.5 0.59 0.12 0.96 0.85 0.43 0.9 0.42 0.35 
Raw score findings for locomotor subscale confirm that scores are similar at 5 years – both raw 
scores and quotients comparisons at time point are in agreement with no statistically significant 




Trajectory of clinical signs in children who developed HIV 
encephalopathy 
HIV Encephalopathy (HIVE) is the most severe form of neurological insult in Children 
perinatally infected with HIV. Since the introduction of ART, the incidence of HIVE has 
decreased and has changed to a less severe form.[43, 44] 
For this longitudinal study of children on the CHER trial, HIVE was recorded as an end 
point. While conducting neurodevelopmental screening assessments on CHER 
participants, it was noted that the clinical course was quite variable. 
In this chapter we describe the trajectory of clinical signs for those CHER participants 
who developed HIVE. Possible associations were explored by comparing demographic 
characteristics of HIVE cases to non-cases.  
Interestingly, HIVE was diagnosed when 80% of cases were on ART and 45% had 
undetectable viral loads for a median [IQR] of 12 [1.4-2.2] years. This has been previously 
described in smaller studies by Tamula and Innes, the latter described participants on the 
CHER trial who are also included in this paper.[45, 46] Upper motor neurone signs were 
the most common (90%), followed by impaired brain growth (80%), gross motor delay 
(95%) and language delay (60%). 
Four children were not on ART, when HIVE was diagnosed, and ART was started. Those 
who were already on ART at diagnosis continued on their current ART regimen as there 
was no alternative at that time. UMN signs recovered in 67% over a median of 3.9 years, 
gross motor delay resolved in 74 % over a median of 1.7 years and language delay 
resolved over a median of 1.9 years in 92 %. However only 31% of those with impaired 
head growth reverted to their original growth trajectories. 
Our finding prompts further questions about the underlying neuropathological 
mechanism for prevention and treatment. 
This manuscript is considered ready for submission. 
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Gradual onset and recovery of HIV-related encephalopathy in perinatally infected 
children after early ART 
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Abstract  
Background: Although the incidence and severity of HIV encephalopathy (HIVE) in children 
has decreased with antiretroviral therapy (ART), the effects of early ART on HIVE are not 
well characterized. We describe the clinical course of HIVE in perinatally-infected children 
receiving early ART.  
Methods: Retrospective case description of participants from Cape Town in the Children 
with HIV Early Antiretroviral therapy(CHER) trial, who developed HIVE with follow-up for 
16 months post-trial.  
Results: Twenty(15%) of 133 participants, who initiated ART at a median age 9 weeks, and 
followed until median age of 6.2 years, developed HIVE.  Virological suppression was at 
median [IQR] of 6[6–19] months later. First deterioration was noticed at a median age of 19 
months, when 16(80%) cases were on ART and 9(45%) had undetectable plasma HIV RNA 
viral load for a median of 12 months.  Upper motor neurone signs were present in 90%, of 
whom 67% recovered over median of 3.9 years and motor delay was present in 95%, of 
whom 74% recovered over a median of 1.7 years. Four participants had persistent spastic 
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diparesis. Language delay was present in 60%, of whom 92% recovered over median 1.9 
years. Impaired brain growth was present in 80%, of whom 31% recovered over median of 
2.0 years. In the 16 participants already on ART at HIVE onset, ART regimens were not 
altered. 
Conclusion: HIV+ children on suppressive ART can develop manifestations of HIVE, the 
most common being motor deficits and impaired brain growth. However, the majority 
experienced improvement, with many resolving completely.  
Introduction 
HIV encephalopathy (HIVE) is the most severe neurological manifestation of HIV in children 
and can be ameliorated by combination antiretroviral therapy (ART) [1, 2]. The following 
patterns were initially described for HIVE: static, plateau or sub-acute progressive [3].   
However, the manifestations and clinical course are variable, presumably related to 
individual differences in the underlying timing of infection and mechanism for neuronal 
insults [4-8]. Early ART initiation dramatically reduces the incidence of HIVE, especially 
when started in the first few weeks of life [9, 10], however HIVE still occurs [11, 12]. We 
report the trajectory of clinical signs in a case series of children from a clinical trial who 
developed HIVE after receiving ART from an early age. 
Methods 
We reviewed the clinical notes of participants from the Children with HIV Early 
AntiRetroviral treatment (CHER) trial [13, 14] with confirmed HIVE, and documented the 
clinical course from earliest deterioration. The CHER trial started in July 2005 and formally 
ended on 31 August 2011 with participants followed for an additional 14 months through 
October 2012. In CHER, 377 infants with CD4 ≥25% and below 12 weeks of age were 
randomized to immediate ART for 40 (ART-40W) or 96 weeks (ART-96W) followed by 
planned interruption, or ART was deferred (ART-Def) until clinical or immunological 
deterioration.  ART comprised Lopinavir/ritonavir (LPV/r), Zidovudine (ZDV) and 
Lamivudine (3TC). The Cape Town site contributed 133 (29.5%) participants.  Beyond the 
trial close-out (September 2011), Cape Town participants remained in active follow-up at 
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the research site. The trial was approved by the Ethics Committees of Stellenbosch 
University, the University of the Witwatersrand and also the Medicines Control Council of 
South Africa.  
On the CHER trial, participants were reviewed clinically every 4 weeks until week 24, every 
8 weeks until week 48 and then every 12 weeks. Review included ART adherence, growth 
monitoring and a neurological examination.  The following developmental milestones were 
assessed annually: gross motor, language, fine motor and personal-social functioning using 
the locally-developed Molteno Adapted Scale (MAS) [15, 16]. More frequent 
neurodevelopmental assessments were performed when an abnormality was suspected.  
HIVE diagnosis was determined using the criteria listed below by a blinded end-point review 
committee (ERC) during the CHER trial and by a team of experts outside of CHER (RvT – 
pediatric neurologist; and CA – pediatric neuroradiologist) and investigators from CHER (BL, 
MFC, EFMD and SI) , after the ERC was disbanded. (see figure 1) 
Criteria for HIVE were at least two of the following three findings in the absence of an 
alternative aetiology: (1) Acquired central motor deficit manifesting as upper motor 
neuron (UMN) signs, specifically: pathological reflexes (abnormally brisk reflexes plus 
abnormal spreading of reflexes, crossed adductor response or sustained clonus), increased 
tone, gait disturbance, ataxia or paresis, with evidence of previously normal neurological 
examination; (2) Impaired brain growth manifesting as acquired microcephaly (reduction 
in serial head circumference z-score (HCZ) below one standard deviation [SD] from 
baseline), or generalized brain atrophy demonstrated on radiological imaging; (3) Failure to 
attain or loss of developmental milestones on 2 consecutive visits 3 months apart, using a 
MAS-derived developmental quotient (developmental age divided by chronological age x 
100) <70 in a developmental domain, with evidence of a previously normal quotient. Pre-
ART criteria from the CDC required only one of the above three findings for a HIVE diagnosis
[17]. However, we used more stringent diagnostic criteria and excluded doubtful or
incomplete cases. Alternative aetiologies were excluded after careful clinical, laboratory and
radiological investigation. In addition, psychosocial, nutritional or maternal causes were
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excluded. We also actively sought to exclude confounders. Social deprivation and lack of 
stimulation from caregivers is common in our setting and could contribute to 
neurodevelopmental delay [18]. As poverty, poor education, depression and HIV associated 
neurological disorder (HAND) may all contribute to mothers not caring adequately for their 
children, we looked for recent changes in the mothers or their circumstances that might 
explain developmental delay. Four participants were excluded on this basis. 
Where neurodevelopmental milestones were recorded in the absence of a MAS, these 
additional milestones were retrospectively plotted to obtain a MAS developmental quotient 
for that individual domain. UMN signs were scored as follows: 0 = Normal; -1 = Brisk 
reflexes; -2 = Extremely brisk or spreading reflexes or increased tone; -3 = Crossed adductor 
response; -4 = Clonus (≥3 beats) or Babinski/up-going plantar response. Gait disturbance 
related to UMN dysfunction was scored -5. UMN function was considered abnormal if UMN 
score was ≤ -2. The presence of brisk reflexes alone was considered insufficient evidence of 
central motor deficit. We considered a child to have neuromotor deficit when there was a 
gross motor quotient of <70 and/or UMN score < -2. 
World Health Organization growth parameter z-scores for age and gender were used to 
determine weight-for-age z-score (WAZ), height-for-age z-score (HAZ), weight-for-height z-
score (WHZ) and body mass index –for-age z-score (BAZ) and head circumference (HCZ) 
(WHO AnthroPlus downloadable calculator, https://www.who.int/growthref/tools/en/). 
We defined the date of first neurological concern, when developmental quotient <70 or UMN 
signs (see above) were first documented. The date of nadir for clinical signs was the date of 
lowest developmental quotient and/or lowest UMN score. The date of first improvement was 
the earliest date where this was documented. Normalization of development was defined as 
return of developmental quotient to ≥90.  Normalization of central motor deficit was defined 
as return of UMN score to zero.   Time to recovery in each domain was calculated from the 
first nadir date in that domain. 
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The onset of acquired microcephaly was defined as the date at which head circumference 
growth departed from the usual z-score line and progressively dropped by >1 SD. Recovery 
was defined as return to within 1 SD of baseline head circumference z-score. 
HIV RNA PCR viral load testing in plasma was performed on stored specimens from 2005 to 
2007 and routinely 3 to 6 monthly after 2007 using a Roche AmpliPrep/Cobas Amplicor 
assay (Roche Molecular Systems, Pleasanton, California). The lower limit of detection was 
400 copies/mL in routine specimens and 40 copies/mL in retrospectively assayed stored 
specimens. Cumulative time with unsuppressed HIV RNA viral load was calculated with the 
assumption that, following an undetectable HIV RNA viral load, viral load remained 
undetectable until the next viral load test.  
Cytomegalovirus (CMV) PCR viral load was measured using the Roche COBAS 
AmpliPrep/COBAS TaqMan (CAP CTM) CMV PCR (Roche Molecular Diagnostics, Branchburg, 
New Jersey) [19]. Children with positive CMV DNA PCR test in whom CMV viral load was not 
measureable were assumed to have a CMV viral load equal to the lower limit of detection 
(150 copies/ml).  
Lymphocyte subsets were measured 3 to 6 monthly using a Beckman Coulter single platform 
lyse no wash procedure using Immunoprep™ reagents with Flow Count™ fluorospheres. 
Cumulative time with low CD4 absolute count or CD4% prior to recovery was defined as 
CD4<1000 cells/mm3 or CD4% <25% for <12 months of age; CD4 <750 cells/mm3 or CD4% 
<20% for 12-35months of age; CD4 <500 cells/mm3 or CD4% <20% for >36months of age. 
Statistical Analysis: 
Frequencies were determined for categorical variables whereas medians and interquartile 
ranges (IQR) were calculated for continuous measures. Categorical measures stratified by 
status of HIVE were compared by the Fishers exact test; continuous measures were 
compared by the t-test for normally distributed data and the Mann-Whitney test for 
skewed data. The progression of upper motor neuron signs is presented graphically 
covering the periods before and after nadir measures. Significance was placed at p<0.05. All 
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statistical analysis was conducted using Stata Statistical Software: Release 15. College 
Station, TX: StataCorp LLC. 
Results 
Overview of cases 
In 133 Cape Town CHER participants followed until median (interquartile range (IQR)) of 
6.2 (4.7–6.6) years of age (range 0.1–7.3), ART was initiated at median age (IQR) of 9 (7–12) 
weeks.  Undetectable HIV RNA viral load (VL) was attained at median (IQR) of 6 (6–19) 
months later. HIVE was recognized in 20 (15%) participants. The origin of cases is depicted 
in figure 1. Cases are compared to non-cases in table 1. For HIVE, the median (IQR) age when 
neurological deterioration was first noticed was 19 (16–22) months. At this time 16/20 
(80%) cases were on ART of which 9/20 (45%) had undetectable VL for median (IQR) 12 
(9–14) months before onset. There were seven on ART with detectable VL. Of the four cases 
not on ART, three were in interruption phase (all ART-40W) and one was not yet on ART 
(ART-Def).  
UMN signs were present in 18 (90%), of whom 12 recovered fully over median (IQR) 3.9 
(2.9–5.0) years, one had partial recovery and four had ongoing spastic diparesis (see table 
2). Gross motor delay was present in 19 (95%) of whom 14 recovered fully over median 
(IQR) 1.7 (1.1–2.6) years, and one was lost to follow up. Language delay was present in 12 
(60%) of whom 11 recovered fully over median (IQR) 1.9 (1.4–2.2) years.  Impaired brain 
growth was present in 16 (80%) of whom five recovered over median (IQR) 2.0 (1.6–2.6) 
years. Progression of neurological deterioration and recovery is presented in table 2. 
Progression of UMN signs is shown in figure 2 and the gross motor quotient in figure 3 for 
HIVE cases. The Supplemental Online Figure presents the pattern of language quotient 
recovery in those affected.  Four cases included were previously described [12]. 
ART regimens were not altered when neurological deterioration was noted as there were no 
alternatives. By the end of follow-up, five cases had switched from trial-prescribed ART 
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(ZDV, 3TC and LPV/r): Three switched to Didanosine, Abacavir and Efavirenz or Nevirapine 
due to assumed virological failure following poor adherence; all later switched back to ZDV, 
3TC and LPV/r following viral resistance testing and achieving an undetectable VL after 
adherence intervention; all three improved neurologically after resuming 1st-line ART and 
achieving viral suppression. One child was switched from ZDV to Stavudine due to anaemia; 
he continued to deteriorate neurologically for 10 months after switch and first neurological 
improvement was noted 17 months after switch. One was switched to Abacavir due to 
asymptomatic hyperlactatemia discovered after full resolution of gross motor abnormalities; 
the mild hyperlactatemia subsequently resolved.  
 
Among the 16 cases with impaired brain growth, HCZ did not return to premorbid levels 
with only five (31%) recovering to within 1 SD of their premorbid HCZ. Median (IQR) HCZ at 
five years of age was 0.1 (-0.2 to +0.5) SD below their baseline HCZ, however this did not 
correspond with neurological recovery. Radiological progression of the seven cases with 
generalized brain atrophy could not be determined as follow-up imaging was not routinely 
performed. Magnetic resonance imaging (MRI) was performed on 17/20 cases to exclude 
alternative diagnoses.  
 
CMV was detectable in seven of 18 cases with an available pre-enrolment plasma specimen, 
of whom only three had a CMV viral load above 150 copies/ml. There was no difference in 
CMV viral load between cases and non-cases (p=0.64) or in the proportion with detectable 
CMV between cases and non-cases (p=0.22). One child with HIVE had CMV pneumonia at two 
months of age with a good response to ganciclovir. Birth weight, nadir WAZ and nadir HCZ 
were lower in cases than non-cases (table 1). 
 
Discussion  
  A new pattern of HIV encephalopathy progression and recovery  
Unlike previous descriptions of HIVE in the early phases of ART availability, we observed 
progressive deterioration over 6 to 12 months, followed by gradual recovery as the most 
common pattern seen.  This is in contrast to partial or no recovery. Gross motor and language 
development recovered over 1 to 2 years and UMN signs resolved over 2½ to 4 years, despite 
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unchanged ART in 16 cases, however three had persistent spastic diplegia. We previously 
reported this recovery pattern in four CHER participants who developed stigmata of HIVE 
which then resolved on continuous ART [12]. Interestingly, 70% did not catch up with head 
growth and persisted on a lower growth percentile. 
The insight that the natural progression of HIVE following early ART is towards recovery is 
important for interpreting intervention studies to improve HIVE outcomes.  This was also 
described for lower limb muscle tone by Mann et al when reviewing cases referred for a HIVE 
natural history study by reviewing medical records. Over time, 13 of 19 children identified 
from a HIVE database had resolved by 2.1 years after the initial visit. All had initiated ART 
under old guidelines and before early initiation was routine [20].  In our study, neither age 
at ART initiation nor cumulative time with unsuppressed HIV RNA PCR viral load were 
significantly different in HIVE cases versus non-cases. The proportion with suppressed HIV 
RNA viral load at last recorded visit was marginally lower in cases versus non-cases, which 
may be related to the longer cumulative time on ART in cases due to earlier ART re-initiation 
following HIVE diagnosis. 
Possible mechanism 
The pathogenesis of HIVE in virally-suppressed children remains poorly understood. 
immunopathological processes may be governed by viral and host factors [21]. HIV crosses 
the blood-brain barrier transported by infected monocytes/macrophages and CD4+ T-
lymphocytes. Astrocytes are then infected and a host inflammatory response leads to a 
neurotoxic cascade that may damage the inflammation-sensitive myelin sheath. While this 
may occur due to infectious virus, it may also occur in its absence. A correlation has been 
found between the severity of cognitive impairment and the degree of tumor necrosis factor 
elevation within astrocytes and microglial cells and the number of activated microglia cells 
in brain tissue [22], but not with the number of HIV-infected cells or the amount of HIV in 
brain tissue. Evidence suggests that the pathogenesis of HIVE in children on suppressive ART 
may be mediated by activated microglial cells and astrocytes over-producing inflammatory 
cytokines in response to persisting viral proteins, particularly gp120 [2, 23]. Conceivably, 
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therefore, white matter demyelination that occurs despite virological suppression may be 
related to such disordered immune regulatory mechanisms. This may plausibly be driven by 
cytokine release in response to antibodies against myelin oligodentrocyte glycoprotein 
(MOG). MOG antibodies are implicated in causing neuroinflammation and demyelination in 
HAND, even after viral clearance [24].  This is consistent with the white matter 
hyperintensities seen on T2/FLAIR MRI in participants on the CHER study [25] (9 from this 
cohort were included). Inflammation may have resolved over time as exposure to HIV 
antigens decreased. 
We postulate that initially the brain infection is relatively well controlled, while later, there 
is a quantitative and/or qualitative breakdown of immune regulation in the CNS. Chronic 
intrathecal immune activation in HIV+ patients has been reported, even after several years 
of ART [26]. Markers of intrathecal inflammation include MOG antibodies, myelin basic 
protein, neopterin, Beta 2-microglobulin, oligoclonal bands and immunoglobulin G index. 
Notably, ART intensification has no effect on intrathecal immunoactivation, a finding that 
argues against ongoing viral replication in the CNS. This finding raises the question whether 
immunomodulatory therapy (at the time of neurological deterioration) may be of benefit; 
however, that spontaneous recovery occurred in most study participants (albeit at a slow 
rate) argues against such a need. Another possible contributing factor, that of ART 
neurotoxicity is unlikely as the children improved on an unchanged regimen. Even though 
protease inhibitors disrupt astrocyte function at therapeutic concentrations in mouse 
models, our participants resolved on unchanged LPV/r [27]. We hypothesise that intrathecal 
inflammation, most likely due to HIV products, contributes to HIVE and that resolution 
occurs after inflammation has resolved. 
The most prevalent HIV-related neurological impairments in the study participants were 
impaired brain growth and pyramidal tract dysfunction (upper motor neuron signs), which 
are consistent with cerebral white matter (myelin) involvement i.e. HIV-related 
leukoencephalopathy. In a neuroimaging DTI study, our group showed predominant 
involvement of corticospinal tracts in CHER HIV+ children at 5 years of age compared to 
uninfected controls [28] (only five of the 17who had neuroimaging in  this study were 
included). HIV-associated oligodentrocyte/ myelin injury has been observed clinically from 
neurological imaging studies and brain biopsies.[29, 30] Myelin injury is also associated with 
56
Stellenbosch University https://scholar.sun.ac.za
blood-brain-barrier deregulation. The normalization of brain growth and disappearance of 
UMN signs in the most children is probably related to cerebral white matter recovery of 
myelin maintenance (re-myelination) during developmental maturation. Mann et al [20], 
and our group [31] demonstrated locomotor recovery with time.  Whatever the cause, the 
extent of recovery in our cases suggests that extensive neuronal loss does not occur and, 
despite visible demyelination, the integrity of neuronal connections is preserved. Further 
studies are warranted to explore this possibility. The sensitivity of standard CNS imaging for 
mild demyelination has been shown to be poor, may highlight the need for functional white 
matter imaging modalities (MR spectroscopy and diffusion tensor imaging) and combining 
with inflammatory markers in unravelling this disease process.  
Limitations  
The CHER trial was not a neurodevelopmental trial and focussed on clinical endpoints 
including mortality. The initial clinical signs may have been subtle in young infants and may 
not have met objective criteria for a study endpoint. Most participants remained in active 
follow-up beyond the trial close-out (September 2011), providing additional data on 
progression of early neurological abnormalities detected during the trial. Unfortunately, we 
did not have prenatal data including information about maternal viral loads and health 
status, we also could not determine if HIV infection was pre- or perinatal, which may have 
contributed to a vulnerable CNS in the developing child. 
We used stringent diagnostic criteria for HIVE, requiring two out of three signs (where CDC 
criteria only requires one), which excluded milder forms of neurocognitive disturbance. The 
MAS developmental milestone scale is not sensitive enough to detect subtle abnormalities 
and it is possible that a more detailed developmental assessment tool may have identified 
additional cases. We did not measure CSF VL and the possibility of low-level CSF viremia 
(<40 copies/ml) could not be excluded. Only structural imaging was performed and while 
radiological assessments of brain atrophy were performed by a single neuroradiologist, final 
assessments of atrophy were subjective. It is possible that volumetric measurements may 




HIVE may occur after early ART initiation and virological suppression and then resolve on 
unchanged ART, most likely as intrathecal inflammation subsides.  
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Table 1: Demographics, therapy, immunological status and anthropometry of HIVE cases 






Gender (male) 8 (40%) 51 (45%) ns 
Receiving nevirapine at birth 17 (85%) 106 (94%) ns 
Receiving zidovudine at birth 18 (90%) 104 (92%) ns 
Birth weight (kg) 2.8 (2.6 – 3.0) 3.0 (2.7 – 3.3) 0.03 
Mode of delivery 
• Normal Vertex delivery 17 (85%) 79 (71%) 
• Caesarean Section 3 (15%)  15 (13%) 
• Unknown 0 19 (17%) 
Baseline log10 HIV RNA viral load (copies/ml) 5.9 (5.8 – 5.9 ) 5.9 (5.6 – 5.9) ns 
Cytomegalovirus detectable in pre-enrolment 
plasma  (specimens available for n=118 
participants (18 cases, 100 non-cases) 
7 (35%)  (n= 18) 25 (22%) (n = 100) ns 
Nadir CD4 (cells/mm3) 688 (446 – 912) 708 (532 – 998) ns 
Nadir CD4% 21% (15 – 25%) 21% (16 – 26%) ns 
Cumulative time with low CD4 or CD4% 
(months) 
5.2 (0.0 – 14.1) 1.5 (0.0 – 8.4) ns 
CHER arm allocation 
 (ART-Def | ART-40W | ART-96W) 5 | 10 | 5 33 | 38 | 42 
ns 
ART- Def treatment status at onset of HIVE: 
• Started ART 4 
• Not yet started ART 1 
ART-40W treatment status at onset of HIVE: 
• On ART not yet interrupted 0 
• On uninterrupted ART (Site decision to
maintain ART)
3 
• In protocol-defined interruption phase 3 
• Previously interrupted and back on ART for
protocol reasons
4 
ART-96W treatment status at onset: 
• On ART not yet interrupted 2 
• On uninterrupted ART (Site decision to
maintain ART)
3 
• In protocol-defined interruption phase 0 
• Previously interrupted and back on ART for
protocol reasons
0 
Age at first ART initiation (months) 2.2 (1.8 – 2.3) 2.1 (1.7 – 2.7) ns 
Cumulative time on ART  (years) § 4.9 (4.8 – 5.2) 4.7 (2.8 – 5.3) ns 
Duration interrupted ART (months) 
(N=20, of which 9 (<50%) had ART interruption) 
0.0 (0.0 – 7.5) 1.8 (0.0 – 7.7) ns 
Cumulative time with unsuppressed HIV RNA 
PCR viral load (years)  
1.7 (1.4 – 3.0) 2.0 (0.9 – 2.8) ns 
Median time in follow-up (years) 6.3 (6.1 – 6.6) 6.2 (2.7 – 6.5) ns 
 Virally suppressed at last recorded visit 17 (85%) 73 (64%) ns 




At trial entry 
Nadir 
-1.0 (-1.9 to -0.7)
-2.1 (-3.1 to -1.6)
-0.9 (-1.8 to 0.0)




At trial entry 
Nadir  
-1.9 (-2.8 to -1.3)
-2.7 (-3.2 to -2.2)
-1.4 (-2.3 to -0.6)




At trial entry 
Nadir 
+0.5 (-0.1 to +1.2)
-1.2 (-2.7 to -0.4)
+0.5 (-0.3 to +1.2)
-0.6 (-1.8 to +0.1)
ns 
ns 
Body mass index -for-age z-score 
At trial entry 
Nadir 
Zenith 
-0.4 (-1.0 to +0.3)
-0.7 (-1.8 to -0.2)
+2.1 (+1.2 to +2.4)
-0.2 (-1.1 to +0.6)
-0.8 (-1.7 to -0.1)




All variables are given as median (interquartile range) unless stated otherwise. Proportions are given 




Table 2: Neurological deterioration and recovery among HIVE cases (n=20): 
Subgroup N affected Full recovery Partial recovery Minimal or no recovery LTFU/No data 
UMN 
Not on ART 4 3 0 1 0 
ART, VL >1000c/ml 6 2 1 3 0 
VL <400c/ml 8 7 0 0 1 LTFU 
Gross Motor 
Not on ART 3 2 1 0 0 
ART, VL >1000c/ml 7 4 3 0 0 
VL <400c/ml 9 8 0 0 1 LTFU 
Language 
Not on ART 2 2 0 0 0 
ART, VL >1000c/ml 6 5 1 0 0 
VL <400c/ml 4 4 0 0 0 
Personal 
Social 
Not on ART 1 1 0 0 1 No data 
ART, VL >1000c/ml 3 3 0 0 1 No data 
VL <400c/ml 0 0 0 0 0 
Fine Motor 
Not on ART 0 0 0 0 1 No data 
ART, VL >1000c/ml 1 1 0 0 1 No data 




Not on ART 
(2  had imaging) 
3 2 0 1 
(2 cortical atrophy) (1 cortical atrophy) (0 cortical atrophy) 
ART, VL >1000c/ml 
(3 had imaging) 
4 2 0 2 
(0 cortical atrophy) (0 cortical atrophy) (0 cortical atrophy) 
VL <400c/ml 
(All had imaging) 
9 1 0 8 
(4 cortical atrophy) (1 cortical atrophy) (3 cortical atrophy) 
 4 cases not on ART at HIVE onset; 7 cases on ART at HIVE onset but viral load >1000c/ml; 9 cases on ART at HIVE onset with viral load <400c/ml. 
 (Note: no participants had viral load between 400 and 1000c/ml at onset) 






























Months before /after nadir
Progression of upper motor neuron signs in those affected
§ Upper motor neuron abnormalities were scored as follows:        
 0 = Normal;   -1 = Brisk reflexes;         -2 = Extremely brisk or spreading reflexes or increased tone;      -3 = Crossed adductor response;    
-4 = Clonus (≥3 beats) or Babinski/up-going plantar response;    -5 = Gait disturbance related to upper motor neuron dysfunction. 




Figure 3: Progression of gross motor developmental quotient on the Molteno adapted scale in those affected (n=19) 
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Neurodevelopment after starting antiretroviral therapy within the 
first few days of life 
As knowledge and experience about treating perinatally infected infants improved, it 
became apparent that early diagnosis and commencing ART as soon as possible after 
birth may be the best option. This on the premise of decreasing reservoir size and 
maintaining immune health [39] and the potential for cure or remission.[47, 48] Early 
diagnosis and treatment programs have been implemented internationally and in South 
Africa.[40, 49] However neurodevelopmental outcomes from very early ART have not yet 
been described. Concern about toxicity to the developing brain persists. [50]  
This fifth chapter reports on the early neurodevelopmental outcome of infants enrolled 
onto the very early infant diagnosis program in Cape Town [51, 52] and followed on an 
NIH funded study (R01MH 105134) to assess the effects of early ART on the HIV reservoir 
size. ART was Abacavir, Lamivudine and Lopinavir/ritonavir.  
Early neurodevelopmental outcomes at 11 months of age for this early treatment cohort 
(commencing ART at a median of 6 days) are reported as a pilot study (n=29) and 
compared to CHER participants on early ART arms (commencing ART at a median of 8 
weeks of age). Mean scores on the GMDS at 11 months are within the normal range and 
are similar to scores from the CHER early ART arms, providing no evidence for ART 
neurotoxicity, after starting very early ART.  
There may be a safe window for favourable neurodevelopmental outcome when starting 
ART before 8 weeks of age. However, the early treatment cohort had more challenges to 
neurodevelopmental outcome than the CHER cohort (in-utero infection, perinatal 
infections and more pre-natal drug exposure) and may possibly have scored higher, 
suggesting that it may be better for neurodevelopmental outcome to start ART as soon 
after birth as possible.  
These should be regarded as preliminary findings in a cohort of only 29 infants. 




Neurodevelopment at 11 months after starting antiretroviral therapy 
within 3 weeks of life 
Authors:  
Barbara Laughton1, Shalena Naidoo2, Els F.M.T. Dobbels1, Michael J. Boivin3, Anita Janse 
van Rensburg1, Richard H. Glashoff Mail4,5, Gert U. van Zyl5,6, Mariana Kruger1,  Mark F. 
Cotton1  
Affiliations: 
1.Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences,
Stellenbosch University, Cape Town, South Africa
2.Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch
University, Cape Town, South Africa
3.Department of Psychiatry and Neurology and Ophthalmology, Michigan State
University, East Lansing, United States
4.Division of Medical Microbiology and Immunology, Department of Pathology, Faculty
of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
5.National Laboratory Services, Cape Town, South Africa
6.Division of Virology, Faculty of Medicine and Health Sciences, Stellenbosch University,
South Africa   
S Afr J HIV Med. 2019;20(1), a1008. https://doi.org/10.4102/sajhivmed.v20i1.1008 
Allocated Journal Section Original Research 
Date submitted YYYY-MM-DD 2019-07-08 




Background: Antiretroviral therapy (ART) started between 7 and 12 weeks of age 
improves neurodevelopmental outcomes in HIV-infected (HIV+) infants, but the impact 
of even earlier initiation is not yet described. 
Objective: We assessed the early neurodevelopment of HIV+ infants who started ART 
within 21 days of life. 
Method: Participants were enrolled from the public sector birth HIV-diagnosis 
programme. Inclusion criteria included the following: birth weight >2000 g, infant 
commencing ART <6 weeks and no infant cytomegalovirus disease. Antiretroviral 
therapy included Zidovudine/Lamivudine/Nevirapine for the first 2 weeks, the latter 
then replaced by Lopinavir/Ritonavir. Once body weight >3 kg and gestational age >44 
weeks, Abacavir replaced Zidovudine. The Griffiths Mental Development Scales (GMDS) 
were administered at 10–12 months. 
Results: Of 29 infants assessed, 23 (79%) were girls. Mean birth weight was 3002 ± 
501g. Twenty-four mothers (83%) received ART during pregnancy. Seven (24%) 
infants were diagnosed HIV+ within 48 h of birth. Median [interquartile range] viral 
load (VL) at diagnosis was 3904 [259–16 922] copies/mL, age starting ART was 6.0 [3–
10] days and age at VL suppression was 19.1 [15–36] weeks. At the GMDS assessment,
nine (31%) participants had detectable VL and 26 (90%) had WHO clinical stage I
disease. Griffiths Mental Development Scale was performed at a mean age of 11.5±0.8
months. Mean quotients were within the average range: Global Griffiths score was
103.6±10.9 and mean quotients on the subscales ranged from lowest 95.9±13.4 for
locomotor to highest 112.8±11.3 for hearing-and-language.
Conclusion: Preliminary findings in this small group suggest that early
neurodevelopmental scores are within the normal range in infants with perinatal HIV




HIV-infected (HIV+) children are at risk for neurodevelopmental delay. Neurologic 
insults develop after HIV enters the brain, creating an inflammatory state affecting 
neuronal and astrocyte growth and development1; the most severe manifestation being 
HIV encephalopathy (HIVE). HIV encephalopathy rates range from 6% to 30%, with 
higher rates in low- and middle-income countries especially with delayed initiation of 
combination antiretroviral therapy (ART).2,3,4,5 These consequences place a great 
burden on the social and healthcare systems. 
Antiretroviral therapy has decreased the incidence of HIVE,6 and when initiated 
between 3 and 9 months of age, it improves clinical and neurodevelopmental 
outcomes.7,8,9,10 Nevertheless, studies describing permanent deficits or lack of catch-up 
suggest that prevention is better than reversal of HIVE.11,12,13 From 2016, the World 
Health Organization (WHO) introduced birth testing and recommended starting ART as 
soon as possible once HIV infection is confirmed.14 Since the report of temporary 
remission in the Mississippi baby after very early ART,15 there is increasing evidence 
that early ART in perinatally infected children improves infant outcomes.16 Early ART 
can limit HIV reservoir size, and when started before 2 months of age, it is associated 
with fewer infected and transcriptionally active cells and less infectious virus 
recovery.17,18,19,20,21,22,23,24 However, administering ART in a neonate and young infant is 
not easy with potential drug resistance because of under-dosing, or neurotoxicity 
because of overdosing.25 The long-term outcomes of very early exposure to ART are still 
unknown. It is therefore imperative that neurodevelopmental testing be undertaken 
after early ART initiation. Our aim was to determine the neurodevelopmental outcomes 
of perinatally HIV-infected children after initiating ART within the first 3 weeks of life. 
Research methods and design 
We report early data from a prospective descriptive study conducted in the Family 
Centre for Research with Ubuntu (FAM-CRU) in Tygerberg Hospital, Cape Town South 
Africa, with recruitment from the Médecins Sans Frontières service in Khayelitsha and 
elsewhere in the public sector.  Antiretroviral therapy was started as soon as HIV 
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infection was confirmed. HIV diagnosis was made by quantitative HIV-1 viral load (VL) 
testing and confirmed by a qualitative HIV-1 RNA PCR. Indeterminate samples were 
repeated until HIV diagnosis confirmation.26,27 Inclusion criteria were the following: 
birth weight >2000 g, commencing ART <6 weeks of age and no infant cytomegalovirus 
(CMV) infection. Mothers or legal guardians were consented in person in their language
of choice according to Good Clinical Practice standards.
Participants were seen as frequently as needed until stable, monthly for 3 months and 
then 3 monthly. Visits included a medical examination, growth monitoring, adverse 
event assessment and social work support where needed. At each visit, a pharmacist 
calculated the percentage adherence for each drug from returned ART containers and 
an adherence counsellor established reasons for over or under-dosing with the parent 
or caregiver, offered advice on problems identified and reviewed measuring techniques. 
HIV viral load was performed at baseline, 3, 6 and 12 months. Undetectable VLs were 
reported as <100 or <40 copies/mL depending on the blood volume available for 
testing. CD4 cell counts were done at 3, 6 and 12 months. Antiretroviral therapy 
comprised Zidovudine, Lamivudine and Nevirapine, with Lopinavir/Ritonavir replacing 
Nevirapine after 2 weeks of age or gestational age of 42 weeks. Once weight exceeded 3 
kg and gestational age was above 44 weeks, Abacavir replaced Zidovudine. Participants 
also received co-trimoxazole from 6 weeks of age. 
The Griffiths Mental Development Scales (GMDS) (0–2 years) were conducted by the 
same developmental paediatrician (BL) at 10–12 months of age.28 The GMDS assesses 
five subscales: locomotor, personal–social, hearing-and-language, eye–hand co-
ordination and performance (visual–motor abilities). A global score, the General 
Griffiths, is also calculated. Raw scores are converted into quotients, derived from 
norms of healthy British children, with a mean of 100 and standard deviation (SD) 16. 
While the GMDS is neither standardised nor validated in South Africa, it is the most 
widely used developmental assessment tool, is considered culturally fair and is used to 
assess young children including those exposed to HIV.29,30,31,32,33,34,35,36 Vision was 
assessed clinically during testing and through the ability to track small cake decorations 
(‘hundreds and thousands’ test), which implies visual acuity of 6/24 or better.37 
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Statistical analysis was performed using Stata release 11 (StataCorp, College Station, 
TX) and Statistica 13 (software.dell.com. Dell Inc. 2015). For descriptive statistics, mean 
and SD were reported for normally distributed data and median and interquartile range 
(IQR) for skewed data. Guided by distribution of the data, Spearman and Pearson 
correlations were used to explore correlation between various parameters and 
neurodevelopmental outcomes. For calculating age at VL suppression, those who had 
not yet achieved VL suppression were assigned a date 2 days after the GMDS. 
Regression analysis explored the contribution of five predictors of GMDS scores: birth 
weight, ART start age, baseline VL, baseline CD4% and age at first VL suppression. 
Descriptive data and GMDS scores were also compared to those from the early 
treatment arms on Children with HIV Early antiRetroviral (CHER) participating in a 
neurodevelopmental sub-study who received early ART from a median of age of 7.7 
weeks and were assessed by the same investigators at 11 months of age.10 
Results 
Of 29 children studied, 23 (79%) were female. Mean birth weight was 3002 ± 501 g and 
gestation was 37.9 ± 2.3 weeks. HIV+ diagnosis was made by 48 h of birth in 7 (24%) 
and within 7 days of birth in 17 (59%) infants. Median [IQR] age for starting ART was 
6.0 [3–10] days (range 0–21) from birth. Twenty-three achieved VL suppression at 
median [IQR] 19.1 [14.7–35.9] weeks of age (range 2–53) (Table 1). 
Griffiths Mental Development Scale was performed at a mean of 11.5 ± 0.8 months 
(range 10.2–13.1) and scores are described in Table 2. Mean GMDS quotients were in 
the average range and within 1 SD of the standardised scores. The locomotor subscale 
had the lowest mean quotient. No children were suspected of having hearing or vision 
problems. 
Clinical status at the time of GMDS is described in Table 3. One child had progressed to 
WHO stage II HIV disease (persistent oral candida), and two to stage III (chronic 
suppurative otitis media and pulmonary TB). Nine children (31%) had detectable VL at 
the time of GMDS testing, six (21%) had not yet achieved viral suppression and three 
had previously suppressed (one at 27 weeks and two at 19 weeks of age), but 
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rebounded to log 5.44 (273 328 copies/mL), log 3.18 (1519 copies/mL) and log 4.46 
(28 649 copies/mL), respectively. Another participant suppressed at 3 months, and had 
a viral blip to 118 copies/mL at 6 months, with the VL undetectable 6 months later at 
GMDS. 
A number of demographic and exposure issues with potential to influence 
neurodevelopmental outcomes were identified. These included two without antenatal 
care, one with an unsupervised home birth and three with maternal substance abuse: 
two methamphetamine and one methamphetamine and alcohol (over time these 
children were fostered by caring relatives). Medical problems included one each of the 
following: congenital pneumonia of unknown aetiology, intrauterine growth 
retardation, neonatal jaundice above exchange transfusion levels (resolved without 
exchange), congenital syphilis with mild hypoxia and suspected seizure, mild birth 
asphyxia (low birth Apgar scores and cord blood pH=7.17) and suspected 
hypoglycaemia (but glucose level not recorded) (these data not shown in any table). 
The following adverse events, which could negatively impact neurodevelopment, were 
documented before the GMDS assessment: six with otitis media (one had two episodes), 
six with anaemia and three with neutropenia (Zidovudine was discontinued). One infant 
recovered fully after treatment for suspected bacterial meningitis and another was 
hospitalised for 6 months with pulmonary tuberculosis. Lastly, failure to thrive because 
of poor feeding and insufficient caloric intake occurred in one infant. 
Adherence was calculated at a median [IQR] of 10 [9–11] visits. Only one participant 
had acceptable adherence percentages for all drugs at all visits. Three participants had 
poor adherence for more than half of the visits, with the rest over or under-dosing at 
various times. For the former, the infant would spit syrups out and caregivers were 
unsure how much to replace. For the latter, the caregivers either measured syrups 
incorrectly or were non-compliant. This prompted clinicians to encourage treatment 
supporters for the caregivers. 
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TABLE 1: Demographic characteristics of participants (N = 29). 
Sex Female = 23 (79%) 
Birth weight (g) 
Mean ± SD 
3002 ± 501 (2150–4070) 
Gestational age (weeks) 
Mean ± SD (range) (3 unknown gestation) 37.9 ± 2.3 (33–41) 
Birth method: vertex delivery 
 Caesarean section 
21 (72%) 
8 
Mother’s age at birth (years) 
Mean ± SD (range) 29.3 ± 5.4 (18.9–40.4) 
History of prenatal substance exposure 2 – Methamphetamine 
1 – Alcohol + methamphetamine 
Home language 21 (70%) Xhosa 
 6 (21%) Afrikaans 
 1 Shona 
 1 English 
PMTCT – mother 24 (83%) Yes 
 4 (14%) No 
 1 Unknown 
Infant age HIV diagnosis (days) 
Median [IQR] (range) 6 [3–12] (0–52) 
Infant age HIV diagnosis: 
 within 48 h 
 within 1 week 
 7 (24%) 
17 (59%) 
Infant ART start age (days) 
Median [IQR] (range)  6.0 [3–10] (0–21) 
ART regimen started n (%) 16 (55%) Zidovudine, Lamivudine, Nevirapine 
 6 (20%) Zidovudine, Lamivudine, 
Lopinavir/Ritonavir 
 7 (24%) Abacavir, Lamivudine, 
Lopinavir/Ritonavir  
Infant baseline VL (copies/mL) 
Median [IQR] (n=26a) 3904 [265–16 922] (range 99–201 916) 
CD4 closest to baseline 
Median [IQR] 
Age (days) 
Absolute count  
CD4% 
14 [9–28] (range 0–251b) 
1938 [1446–2570] (range 679–3776) 
43 [35–56] (range 19.6–71) 
Time to undetectable VLc (weeks from birth) 
Median [IQR] (range) 19.1 [15–34] (2–53) (n = 23d) 
a3 only had HIV PCR+ and no VL measured. 
bParticipant only enrolled onto study at this age – only had VL before and no CD4 counts. 
cVL done at baseline/diagnosis, 3, 6, 12 and 18 months. 
dSix did not suppress by time of GMDS assessment. 
Source:Authors’ own data compilation from this study 
VL, viral load; IQR, interquartile range; ART, Antiretroviral therapy; PMTCT, prevention of 
mother-to-child transmission; SD, standard deviation; GMDS, Griffiths Mental Development Scale. 
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TABLE 2: Scores on Griffiths mental development scales (quotients) at mean age 
of 11.5 months (n = 29). 
Scale Mean SD Maximum Minimum 
Locomotor 95.9 13.4 125 74 
Personal–social 104.2 14.7 138 72 
Speech and hearing 112.8 11.3 131 85 
Eye–hand coordination 105.0 17.5 136 60 
Performance (visual–spatial) 99.1 15.7 133 68 
General Griffiths 103.6 10.9 123 82 
Norms from healthy British children: mean 100 ± 16 
Source: Authors’ own data compilation from this study 
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TABLE 3: Clinical status at the time of neurodevelopmental assessments (N = 29). 
Age: Mean ± SD (range) 11.5 ± 0.8 months (range 10.2–13.1) 
HIV disease severity: WHO categories 1 = 26 (90%) 
2 = 1 
3 = 2 





-0.09 ± 0.9 (range -1.7 to 1.6)
-1.1 ± 1 (range -3.5 to 0.2)
0.23 ± 1 (range -1.9 to 2.4)
ART regimen 29 Abacavir, Lamivudine, 
Lopinavir/Ritonavir 
VL undetectable, n (%) 20 (69%) 
CD4 closest to GMDS Median [IQR] 
 Absolute count 
 CD4% 
2097.9 [743–1512] (range 863–3790) 
33.8 [27–41] (range 18–53) 
CD8 closest to GMDS Median [IQR] 
 Absolute count 
 CD8% 
1489 [1131–2437] (range 608–7551) 
27 [21–34] (range 13–53) 
CD4/CD8 ratio closest to GMDS 
Median [IQR] 1.33 [0.83–1.92] (0.38–3.79) 
Current caregiver n (%) 23 (79%) mother 
1 shared mother and grandmother 
2 aunt  
1 foster mother 
2 grandmother 
Father or father-figure present, n (%) 
Caregiver/father/father-figure  
Drugs or alcohol abuse, n (%) 
Housing, n (%):  
 Brick 
 Informal dwelling  
Electricity in house, n (%) 
Household receives social grants, n (%) 
20 (69%) 





Source: Authors’ own data compilation from this study 
IQR, interquartile range; SD, standard deviation; GMDS, Griffiths Mental Development Scale. 
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Correlations between GMDS scores and possible predictors of developmental outcomes 
(birth weight, gestation, maternal age, baseline VL, age starting ART, time to 
suppression and CD4 parameters at baseline) were not significant. The five predictors 
of GMDS scores entered into the regression model also did not show significant 
relationships, that is, birth weight, ART start age, baseline VL, baseline CD4% and age at 
first suppression. CD8 count at the time of GMDS showed a negative correlation with 
personal–social (Pearson r=-0.41; p=0.03) and a negative trend with General Griffiths 
(Pearson r = -0.6; p = 0.06). 
For growth parameters closest to the Griffiths assessment, head circumference z-scores 
correlated significantly with the Performance (visual–spatial) scores (Pearson’s r = 0.4; 
p = 0.02) and weight z-score correlated with eye–hand coordination scores (Pearson’s r 
= 0.36; p = 0.05). There was a positive trend between weight for age z-score and General 
Griffiths score (Pearson’s r = 0.34; p = 0.07). 
We compared the GMDS scores of those whose mothers had ART for prevention of 
mother-to-child transmission of HIV (PMTCT) and those who did not and found no 
difference between the groups (see Supplementary Table 1). There were also no 
significant differences on the GMDS scores between those with detectable VL and 
undetectable VL at the time of the test, despite the mean scores in the hearing-and-
language and eye–hand coordination subtests being 5 points lower for the nine with 
detectable VL compared to the 20 with undetectable VL at testing (Table 4). We also 
compared the following participant demographics between the detectable VL and 
undetectable VL groups: birth weight, baseline VL copies and CD4 parameters, ART 
start age, CD4, CD8 and growth parameters at the time of GMDS, and found no 
difference (see Supplementary Table 2). 
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TABLE 4: Comparison of Griffiths mental development scale quotients in those with 
and without virological suppression at testing. 
Viral load at testing Detectable VL 
n = 9 
Undetectable VL 
n = 20 
p* 
Mean age at testing (months) 11.4 11.5 
Locomotor 96.9 ± 13.5 95.4 ± 13.7 0.65 
Personal–social 102.2 ± 13.9 105.1 ± 15.2 0.48 
Hearing-and-language 109.2.4 ± 10.2 114.4 ± 11.6 0.32 
Eye–hand coordination 101 ± 18.4 106.9 ± 17.3 0.46 
Performance (visual–spatial) 97.9 ± 14.9 99.1 ± 16.4 0.94 
General Griffiths 101.8 ± 10.4 104.4 ± 11.3 0.52 
Source: Authors’ own data compilation from this study 




Griffiths Mental Development Scales scores achieved by this cohort were similar to 
those from the CHER cohort (children on ART commenced at 7 weeks of age) at a mean 
age of 11.3 months, apart from personal–social subscale, where the CHER cohort had 
mean quotients 7 points above that of the current study population (Table 5). Post hoc 
item comparison for personal–social showed that CHER participants were more likely 
to help with dressing, hold an open cup for drinking, try to use a spoon for feeding and 
obey simple requests. Participants on the current study were more likely to clap hands 
and enjoy an adult showing a book. 
Significant differences between the two groups are shown in Table 5, with CHER having 
higher VLs and lower CD4 counts at baseline and a longer time to undetectable VL 
compared to participants in the current study. Abacavir also replaces Zidovudine use in 
the CHER participants. 
84
Stellenbosch University https://scholar.sun.ac.za
TABLE 5: Comparison between study participants and Children with HIV Early 
antiRetroviral early treatment participants.1  
Current study CHER early ART p 
Number enrolled 29 64 
Age of ART initiation 
Median [IQR] 6.0 [3–10] days 7.7 [7.1–9.5] weeks <0.001 
Birth weight (g) 3002 ± 501 2994 ± 406 0.98 
Gestational age 
(weeks)  
37.9 ± 2.3 
(3 unknown) 
38.9 ± 2.3 
(3 unknown) 0.06 





 4 (14%) 
 1 (3%) 
55 (86%) 
 6 (9%) 
 3 (5%) 
History of prenatal 
substance exposure 
2 Methamphetamine  
1 Alcohol+methamphetamine 2 Alcohol 
Infant baseline 
 VL (copies/mL) 2494 ± 47629 (n = 26) 5 500 942 ± 55 693 <0.01a
 CD4 absolute count 2090 ± 800 2062 ± 1100  0.42 
 CD4% 44.7 ± 14.2  35.2 ± 8.6 <0.01 
Time to undetectable 
VLb (weeks) 30.0 ± 16.6 (n = 23) 38.8 ± 8.8 0.01 
ART regimen at the 
time of test 
28 Abacavir, Lamivudine, 
Lopinavir/Ritonavir 








VL undetectable at 
GMDS test 20 (69%) 40 (62%) 
Age at GMDS 
(months) 11.5 ± 0.8 11.3 ± 1.1 0.16 
GMDS quotient scores: 
Locomotor  95.9 ± 13.4  97.7 ± 12.5 0.3 
Personal–social 104.2 ± 14.7 111.2 ± 13.5 0.04 
Speech and hearing 112.8 ± 11.3 112.5 ± 10.4 0.89 
Eye–hand coordination 105.0 ± 17.5 107.4 ± 15.8 0.66 
Performance (visual spatial)  99.1 ± 16.1 100.3 ± 13.1 0.4 
General Griffiths 103.6 ± 11.0 106.2 ± 10.4 0.21 
Norms from healthy British children: mean 100 ± 16 
Source: Ref [1]. Authors’ own data compilation from this study combined with previous 
work (reference no 10) VL, viral load; IQR, interquartile range; ART, Antiretroviral therapy; 
PMTCT, prevention of mother-to-child transmission; SD, standard deviation; GMDS, Griffiths 
Mental Development Scale; CHER, Children with HIV Early antiRetroviral. 
Results expressed as mean ± SD. a Mann–Whitney U.  b For those not yet suppressed at 




These findings from the first 29 infants who started ART at a median age of 6 days are 
encouraging and show potential for normal neurodevelopmental outcomes, despite 
other medical conditions in nine infants that may impair neurological development. 
These scores are well within 1 SD of the UK norms, and are comparable to other South 
African infants assessed at similar ages using the GMDS29,30,32,33,34 (see Supplementary 
Table 3 for summary of scores). This finding is despite almost a third not being 
virologically suppressed at testing. However, VLs in this cohort indicated low exposure 
to HIV because of maternal ART.38 
We previously described neurodevelopmental outcomes in the CHER trial at 11 
months.10 We compared children on delayed ART to those who started early ART at a 
median [IQR] of 7.7 [7.1–9.5] weeks. The GMDS scores from the CHER early treatment 
arms are comparable to this very early treatment group, apart from the personal–social 
subscale (Table 5), which is the most subjective as caregiver report items are used, and 
may reflect a change in child-rearing practices over time with less emphasis on self-care 
skills. The CHER early treatment arms had a mean baseline VL of log10 copies/mL 5.64 
which is far higher than the current study and baseline mean CD percentage of 35% 
which is lower than the current study, and longer time to undetectable VL. This may 
suggest that there is a safe window period for starting ART – between birth and a 
median of 7.7 weeks; however, these are early neurodevelopmental outcomes. 
Alternatively, were it not for adverse in utero exposures and non-suppressed VLs in six 
infants, the scores may have been higher than CHER early treatment participants. The 
early diagnosis of HIV+ infants within 48 h in 24% and by 7 days of age in 59% reflects 
high proportion of prenatal HIV –infection, which also negatively impacts outcomes. In 
the CHER trial, in utero infection could not be assessed as infant screening began at 4–6 
weeks of age for HIV. 
An important finding is that we identified a number of challenges within the context of 
perinatal HIV infection, despite good PMTCT programmes. In those perinatally infected 
infants, a number of secondary effects, including systemic illnesses and environmental 
affects, may negatively impact a child’s early neurodevelopment.39,40,41 In our sample, 
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we identified three with no prenatal care, three substance abuse, two congenital 
infections (syphilis and pneumonia of unknown aetiology), one co-infected with 
tuberculosis and one nutritional failure. Growth in participants was appropriate for 
weight and head circumference, but mean length z-score was -1.1. 
We noted variability of ART adherence and the delay in attaining competence with ART 
dosing and adherence, with six children not yet suppressed at the time of GMDS 
assessment. Management of these young children was challenging as caregivers were 
non-compliant, under-skilled and found difficulty administering liquid formulations. 
Solid or dispersible formulations would certainly improve adherence.42,43 Our findings 
do not suggest neurotoxicity from ART. 
This work had some limitations. As multiple factors may influence outcomes, 29 
children starting ART very early are too few to assess weak associations with 
neurodevelopmental outcomes, including our finding of lower locomotor scores 
compared to other subscales. More girls than boys were enrolled in the sample; 
although previously described,44 this may be because of small sample size. We were not 
able to determine reliable predictors for neurodevelopmental outcomes, or compare the 
outcomes of suppressed and unsuppressed participants. This was also hindered by time 
to suppression being inaccurate as VLs were only done at baseline 3, 6 and 12 months. 
We did not collect information on maternal health, immune status, VL or antiretroviral 
therapies. In the absence of South African normative data on the GMDS, a control or 
comparison group would have been helpful. However, we have experience in this 
community using the GMDS and are able to use these for comparison30,32 
(Supplementary Table 3). The confounding problems of mothers with substance abuse 
did not seem to have a major impact, but the limitation is probably sample size. 
Our findings are relevant to upscaling neonatal HIV identification and care.45,46 While 
the number of HIV+ infants is decreasing, this population remains at high risk because 
of structural and behavioural challenges in providing appropriate care. As liquid 
Lopinavir/Ritonavir formulation is poorly tolerated, newer formulations and other 
alternatives such as integrase inhibitors will be better accepted. Healthcare planners 
should not downscale programmes according to decreasing numbers, as those failing 
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PMTCT require a higher level of care and intensive intervention to enable benefit from 
early ART. With the potential of early ART to limit HIV reservoir seeding, and potential 
to contribute to functional cures, treatment programmes need to support these 
vulnerable infants and their caregivers.47 Mentor mothers as treatment supporters may 
decrease the burden of HIV care and consequences of developmental delay, and could 
be very important when planning programmes. If these needs can be met, our findings 
are encouraging.48,49 
Conclusion 
Preliminary findings in this small group suggest that despite PMTCT failure, children 
infected perinatally with HIV may have typical neurodevelopment if starting ART at a 
median age of 6 days, and similar to those starting ART at a median of 7 weeks. Good 
supportive care, including for ART adherence, is essential. A larger cohort that includes 
controls is in study and the findings at 18 months of age will inform on the influence of 
time to VL suppression and reservoir size and also the influence of social factors and 
demographic factors on neurodevelopmental outcomes. This may also allow for more 
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SUPPLEMENTARY TABLE 1: Comparison of Griffiths mental development scales 
quotients in those whose mothers had antiretroviral therapy for prevention of mother-to-
child transmission of HIV or not reported as mean (standard deviation). 
Yes PMTCT 
N = 24 
No PMTCT 
N = 4 
p 
Locomotor 96.9 (14) 92 (15) 0.51 
Personal–social 104.0 (15) 111.8 (6) 0.22 
Hearing-and-language 112.1 (12) 118.0 (8) 0.34 
Eye–hand coordination 107.5 (16) 101.5 (7) 0.38 
Performance (visual–spatial) 101.5 (15) 90 (4.7) 0.06 
General Griffiths 104.6 (11) 103.3 (3) 0.84 
Source: Authors’ own data compilation from this study 
PMTCT, prevention of mother-to-child transmission. 
SUPPLEMENTARY TABLE 2: Comparison of participant characteristics for those who 
had detectable and undetectable viral loads at Griffiths mental development scales testing 
reported as mean (standard deviation). 
Viral load at testing Detectable VL 




Birth weight 2912.2 (576) 3042.5 (475) 0.37 
Baseline VL copies 45105 (70493) 
(n = 8) 
16000 (318345) 
(n = 18) 
0.36 
ART start days from birth 9.3 (6.4) 5.8 (3.8) 0.14 
CD4 closest to GMDS 








CD8 closest to GMDS 








CD4/CD8 ratio closest to GMDS 1.2 (0.6) 1.6 (0.8) 0.21 
CD4%/CD8% ratio closest to GMDS 1.15 (0.6) 1.6 (0.9) 0.17 
CD4 baseline 





















Source: Authors’ own data compilation from this study 
ART, Antiretroviral therapy; GMDS, Griffiths Mental Development Scale; VL, viral load. 
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SUPPLEMENTARY TABLE 3: Summary of scores on the Griffiths mental 
development scales locomotor and General Griffiths from controls on South African 
studies at similar ages.  
Author/Study Age Locomotor General Griffiths 
Perez: non-anaemic controls34 9 months 136 127 
Davies: non-foetal alcohol 
syndrome controls33 
7–12 months 100 104 
Laughton: HIV exposed 
uninfected controls10 
11 months 102 107 
Current study 11 months 95.9 103.6 
Amod: South African sample29 13–16 months 98 102 
Springer: HIV exposed 
uninfected controls32 
17–19 months 87 87 
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Conclusion and future directions: 
The aim of this dissertation was to explore the effects of different ART treatment 
strategies on the early neurodevelopment of children perinatally infected with HIV. We 
compared the neurodevelopment of participants on various ART treatment strategies on 
a prospective longitudinal study and on a cross-sectional pilot study and found that: 
• Early ART is better than deferred ART for early motor and global development
• Commencing ART early (before 12 weeks of age) followed by closely planned and
monitored ART interruption at 1 year or 2 years of age, using CD4 counts,
appeared safe as neurodevelopmental outcome at 5 years was similar to
uninfected neighbourhood controls.
• Perinatally infected children, starting ART in the first few days of life, have normal
developmental outcomes at 11 months of age.
• Early developmental delay may recover after starting ART.
• HIVE may develop regardless of ART treatment strategy, which may resolve, and
this requires further investigation.
• Visual perceptual deficits at 5 years of age may develop regardless of ART
treatment strategy
These findings have contributed to contemporary knowledge of ART treatment strategies 
for children perinatally infected with HIV. 
There was no evidence to support toxicity of ART to the developing brain, or possibly the 
benefit may outweigh the risk, with minor effects undetected on the GMDS. We should 
continue to monitor for effects of ART.  
Our findings are supported by more recent studies showing improved neurodevelopment 
in infants treated early and with early viral suppression, suggesting that starting ART at 
4 – 6 months of age may be too late.[53-57] Further studies have also support planned 
treatment interruption in older children.[58, 59] 
In five-year old children perinatally HIV infected, visual perceptual deficits were 
recognised regardless of ART treatment strategy. This finding is concerning as visual 
perceptual abilities are important for future educational outcomes.[60] Further 
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investigation is required to determine the timing of pathogenic pathways to this 
neurologic insult in order to identify predictors of poor outcome to prevent or remediate 
as early as possible. 
The small sample sizes in the comparison groups for neurodevelopmental outcome, as 
well as a survivor effect in the delayed treatment group, are a limitation to interpretation 
of results. Important co-morbid factors such as poverty, nutrition and child and maternal 
illnesses, which may have impacted on neurodevelopment were only addressed 
superficially, although were mitigated by randomization of arms in the CHER trial.  
While we may infer that many children were prenatally infected with HIV, we did not 
have documented evidence in most cases, and some infants may have been infected 
during birth or afterwards through breast feeding. 
This study did not address the effects of different antiretroviral drugs and CNS 
penetration, as most children were on the same regimen.[43, 61] Other HIV related 
factors should also be considered in future studies such as: viral and host genetics, time 
to viral suppression, reservoir size formation and the host immune response. Longer 
term outcomes are needed to address effects on brain maturation and children’s abilities 
that cannot be measured in the pre-school age group. 
It is essential to note that there are multiple influences on a child’s neurodevelopment of 
which timing of ART initiation is only one.[62] Contextual factors such as prenatal care of 
mothers, maternal nutrition and mental health are important. For the child, a nurturing 
home environment, adequate nutrition and timeous intervention for illnesses and 
developmental delay all play a role in early neurodevelopmental outcomes.[63-65]  
Considering the above findings, future studies should be conducted to assess the longer-
term effects of different early ART treatment strategies on childhood cognitive, 
behavioural and educational outcomes. Early effects on the structural foundations of the 
developing brain may only become apparent when measuring skills that are expected to 
develop in an older child. These deficits are described in HIV infected school-aged African 
children who started ART after 6 months of age.[66] Further studies should include 
measuring the effects on neurodevelopment of the viral reservoir, host inflammatory 
response and the influence of contextual factors as mentioned above. Identifying early 
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predictors of poor outcomes are the first step for planning effective intervention 
programs.  
In conclusion, starting children on ART whilst asymptomatic has encouraging 
neurodevelopmental outcome at 5 years, apart from visual perceptual deficits which are 
noted regardless of ART treatment strategy. Planned treatment interruption does not 
affect outcome by 5 years of age, however this needs careful clinical guidance. Our 
findings support global initiatives for decreasing the HIV testing and treatment gaps for 
infants and children.[40, 67] Longer term outcomes in older children will continue to 
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Table 3. Nomenclature and research case definitions for neurologic manifestations of 
human immunodeficiency virus-type 1 (HIV-1) infection. (from: Janssen RS, Cornblath DR, 
Epstein LG, Foa RP, McArthur JC, Price RC and the working group of the American Academy of 
Neurology AIDS Task Force. Neurology 1991,41:778-785.) 
HIV-1-Associated progressive encephalopathy of childhood 
Probable ( must have each of the following): 
1) Evidence for systemic HIV-1 infection:
a) Infants and children <15 months
i) Virus in blood or tissues, or
ii) Presence of HIV-1 antibody
and
evidence of cellular and humoral immune deficiency
or
other conditions meeting CDC case definition for AIDS
b) Children ≥15 months
i) Antibody or virus in blood or tissues
2) At least one of the following progressive findings present, at least 2 months
a) Failure to attain or loss of developmental milestones or loss of intellectual ability,
verified by standard developmental scale or neuropsychological tests.
b) Impaired brain growth ( acquired microcephaly or brain atrophy demonstrated on
serial CT or MRI)
c) Acquired symmetric motor deficits manifested by two or more of the following:
paresis, abnormal tone, pathological reflexes, ataxia, or gait disturbance
3) Evidence of another etiology, including active CNS opportunistic infection or malignancy,
must be sought from history, physical examination, and appropriate laboratory and
radiologic investigation (dg. Lumbar puncture, neuroimaging). If another potential
etiology is present, it is not thought to be the cause of the above
cognitive/motor/behavioural/developmental symptoms and signs.
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Possible (must have one of the following): 
1) Other potential etiology present ( must have each of the following):
a) As above (see Probable) #1 and 2.
b) Other potential etiology is present but the cause of #2 is uncertain
2) Incomplete clinical evaluation (must have each of the following):
a) As above (see Probable) #1 and 2.
b) Etiology cannot be determined (appropriate laboratory or radiologic investigations
not performed).
Appendix 2: 
Sample size calculation: 
The locomotor subscale was used as it was expected that locomotor development would 
have the worse outcome. Griffiths scores are standardised with a mean of 100 and 
standard deviation of 15. 
Table 1: Predicting expected mean quotients (locomotor subscale) using results 
from other studies 
Age at Griffiths testing 10 – 11 
months 






Arm 1 ( delayed therapy) 801 801 674 685 
Arms 2 & 3 combined (hoping 
there will be no difference)6 
90 92 92 87 
Exposed and uninfected controls 2 100 100 98 96 
Unexposed and uninfected 
controls3 
110 110 110 110 
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Notes for Table 1: 
1. Results from children on different Nucleoside Antiretroviral Regimes, (these are
results of the Bayley on children < 30.5 months of age). The baseline before
starting treatment was 80 ± 21 ,(Raskino et al 1999)
2. Molteno et al (1991) in their article on the Preschool development of children in
Cape Town, showed that at 12 months development correlated with family
stability, and at 30 months it was associated with mother’s education and family
stability. The Griffiths scores can also look good at 1 year and then deteriorate it
is part of “natural decline”.
3. South African children tend to achieve their motor milestones earlier than average
4. Smith showed the mean baseline for Locomotor on the Griffiths was 67 for
locomotor before starting HAART on children at Red Cross Hospital, Cape Town.
At follow up after 6 months the scores had not improved. (19 of the 26 children
assessed were below 4 years of age).
5. Smith also showed that the patients did not improve after treatment, although
they remained static and did not deteriorate further (This is a bit of a skewed
result as there were some who did worse who were not tested and not included
in the results - those that died or were not too ill to be tested).
6. Shanbhag et al (2005) studied the effects of combined therapy on neurocognitive
functioning. For those diagnosed as neurocognitively healthy, neurocognitive
scores remained stable over time with a mean standard score of 89.6 ± 11.8 at first
evaluation and 91.9 ± 11.9 at most recent evaluation. I am going to use these
scores for the children on early treatment, i.e. they seem neurocognitively healthy
to us but there are deficits. Combined results were also given for the whole group
(neurocognitively healthy and encephalopathies) born after January 1996 and
their score was 87.2 ± 10.49, hopefully our patients will be well, and stable until
3.5 years and only at 5 years we will start picking up the problems.
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Figure 1 shows the sample size vs average effect size for the different power values 
for 5 groups. For a sample size of 40 per group, we should be able to pick up an 
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List of abbreviations: 
ART Antiretroviral therapy 
ART – 40W CHER study arm starting antiretroviral therapy early and interrupting at 
40 weeks on study (close to first birthday) 
ART- 96W CHER study arm starting antiretroviral therapy early and interrupting at 
96 weeks on study (close to second birthday) 
ART- Def CHER study arm starting antiretroviral therapy when clinical or 
immunological criteria are met (ART is deferred) 
CDC Centers for Disease Control and Prevention (CDC) 
CHER Children with HIV early antiretroviral trial 
CHEU Children perinatally HIV exposed and uninfected 
CHEU Children perinatally HIV unexposed and uninfected 
CNS Central Nervous System 
CSF Cerebrospinal fluid 
GMDS Griffiths Mental Development Scales 
HAART Highly Active Antiretroviral Therapy 
HIV Human Immunodeficiency Virus 
HIV+ HIV-positive 
HIVE HIV encephalopathy 
PMTCT Prevention of mother to child transmission 
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